0001493152-18-015120.txt : 20181102 0001493152-18-015120.hdr.sgml : 20181102 20181102123112 ACCESSION NUMBER: 0001493152-18-015120 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181102 DATE AS OF CHANGE: 20181102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTRX CORP CENTRAL INDEX KEY: 0000799698 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581642750 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15327 FILM NUMBER: 181156205 BUSINESS ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 BUSINESS PHONE: 310-826-5648 MAIL ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to __________

Commission file number 0-15327

CytRx Corporation

(Exact name of Registrant as specified in its charter)

Delaware

58-1642740

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

11726 San Vicente Blvd., Suite 650

Los Angeles, CA

90049

(Address of principal executive offices)

(Zip Code)

(310) 826-5648

(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer [ ]	Accelerated filer [X]	Non-accelerated filer [ ]	Smaller reporting company [ ]
Emerging growth company [ ]	(Do not check if a smaller reporting company)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes [ ] No [X]

Number of shares of CytRx Corporation common stock, $0.001 par value, outstanding as of November 2, 2018: 33,637,501 shares.

CYTRX CORPORATION

FORM 10-Q

TABLE OF CONTENTS

	Page
PART I. — FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements (unaudited)	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3. Quantitative and Qualitative Disclosures About Market Risk	20
Item 4. Controls and Procedures	20

PART II. — OTHER INFORMATION
Item 1. Legal Proceedings	21
Item 1A. Risk Factors	21
Item 6. Exhibits	21

SIGNATURES	22

INDEX TO EXHIBITS	23

PART I — FINANCIAL INFORMATION

Item 1. — Financial Statements

CYTRX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

	September 30, 2018			December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	$	24,668,339		$	37,643,404
Receivables		5,981,040			7,529,032
Prepaid expenses and other current assets		1,252,186			1,914,077
Total current assets		31,901,565			47,086,513
Equipment and furnishings, net		646,500			1,042,892
Goodwill		183,780			183,780
Other assets		34,334			34,334
Total assets	$	32,766,179		$	48,347,519
LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	2,900,758		$	4,122,017
Accrued expenses and other current liabilities		7,515,258			8,029,274
Deferred revenue		—			6,924,353
Warrant liabilities		—			527,025
Term loan, net		—			10,599,795
Total liabilities		10,416,016			30,202,464

Commitments and contingencies

Stockholders’ equity:
Preferred Stock, $0.01 par value, 833,334 shares authorized, including 4,167 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding		—			—
Preferred Stock, $1,000 stated value, 650 shares authorized, no shares issued and outstanding		—			—
Common stock, $0.001 par value, 41,666,667 shares authorized; 33,637,501 shares issued and outstanding at September 30, 2018; 28,037,501 shares issued and outstanding at December 31, 2017		33,637			28,037
Additional paid-in capital		476,843,206			468,969,445
Accumulated deficit		(454,526,680	)		(450,852,427	)
Total stockholders’ equity		22,350,163			18,145,055
Total liabilities and stockholders’ equity	$	32,766,179		$	48,347,519

The accompanying notes are an integral part of these condensed consolidated financial statements.

CYTRX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
Revenue:
Licensing revenue	$	250,000		$	—		$	250,000		$	—

Expenses:
Research and development		909,712			4,755,191			3,186,839			17,675,079
General and administrative		2,360,996			3,418,808			6,514,107			9,534,872
		3,270,708			8,173,999			9,700,946			27,209,951

Loss before other income		(3,020,708	)		(8,173,999	)		(9,450,946	)		(27,209,951	)

Other income (loss):
Interest income		93,391			119,900			269,299			271,292
Interest expense		(363,086	)		(828,120	)		(1,715,733	)		(2,999,230	)
Other (loss), net		(641	)		(6,055	)		(5,848	)		(16,722	)
Gain (loss) on warrant derivative liabilities		—			3,763,855			527,025			(572,209	)

Net loss	$	(3,291,044	)	$	(5,124,419	)	$	(10,376,203	)	$	(30,526,820	)

Basic and diluted net loss per share	$	(0.10	)	$	(0.19	)	$	(0.34	)	$	(1.33	)

Basic and diluted weighted-average shares outstanding		32,991,506			26,618,098			30,242,788			22,936,843

The accompanying notes are an integral part of these condensed consolidated financial statements

CYTRX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months Ended September 30,
	2018			2017
Cash flows from operating activities:
Net loss	$	(10,376,203	)	$	(30,526,820	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		407,870			492,944
Stock-based compensation expense		1,367,210			2,214,533
Fair value adjustment on warrant liabilities		(527,025	)		572,209
Amortization of loan cost and discount		1,157,817			1,363,566
Loss on retirement of fixed assets		—			424,050
Changes in assets and liabilities:
Receivables		1,547,992			(256,474	)
Prepaid expenses and other current assets		661,891			1,430,644
Accounts payable		(1,221,259	)		(1,372,697	)
Deferred revenue		—			6,924,353
Accrued expenses and other current liabilities		(736,419	)		(1,124,798	)
Net cash used in operating activities		(7,718,126	)		(19,858,490	)

Cash flows from investing activities:
Purchases of equipment and furnishings		(11,478	)		(134,598	)
Net cash used in investing activities		(11,478	)		(134,598	)

Cash flows from financing activities:
Proceeds from public offering		6,512,151			13,951,218
Proceeds from sale of common shares and warrants related to NantCell		—			6,075,647
Loan end fee payment		(1,771,250	)		(200,000	)
Payment of principal on term loan		(9,986,362	)		(14,000,478	)
Net proceeds from exercise of warrants and stock options		—			3,202,858
Net cash provided by (used in) financing activities		(5,245,461	)		9,029,245

Net decrease in cash and cash equivalents		(12,975,065	)		(10,963,843	)
Cash and cash equivalents at beginning of period		37,643,404			56,959,485
Cash and cash equivalents at end of period	$	24,668,339		$	45,995,642

Supplemental disclosure of cash flow information:

Cash paid during the year for interest	$	647,308		$	1,749,174

Cash paid for income taxes	$	800		$	800

Supplemental disclosure of non-cash activities:

Warrant liability exercise	$	—		$	1,894,589

Warrants repriced in connection with debt modification	$	—		$	76,549

One for six reverse stock split	$	—		$	138,187

The accompanying notes are an integral part of these condensed consolidated financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2018
(Unaudited)

1.	Description of Company and Basis of Presentation

CytRx Corporation (“CytRx,” “we,” “us” or “the Company”) is a biopharmaceutical research and development company specializing in oncology. The Company’s focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor.

During 2017, CytRx’s discovery laboratory, located in Freiburg, Germany, synthesized and tested over 75 rationally designed drug conjugates with highly potent payloads, culminating in the creation of two distinct classes of compounds. To date, four lead candidates have been selected based on in vitro and animal preclinical studies, stability, and manufacturing feasibility. Additional animal efficacy and toxicology testing of these lead candidates is underway.

On June 1, 2018, CytRx launched Centurion BioPharma Corporation (“Centurion”), a private wholly owned subsidiary, and transferred all of its assets, liabilities and personnel associated with the laboratory operations in Freiburg, Germany. In connection with said transfer, the Company and Centurion entered into a Management Services Agreement whereby the Company agreed to render advisory, consulting, financial and administrative services to Centurion, for which Centurion shall reimburse the Company for the cost of such services plus a 5% service charge. The Management Services Agreement may be terminated by either party at any time. Centurion is focused on the development of personalized medicine for solid tumor treatment.

There are two key elements to Centurion’s strategy:

	1.	A novel companion diagnostic, ACDx™ (albumin companion diagnostic), developed to identify patients with cancer who are most likely to benefit from treatment with Centurion’s lead assets.

	2.	Development of its four albumin binding, linker activated drug release (LADR) oncology candidates.

Personalized medicine requires diagnostic and therapeutic approaches utilized together in order to select the right patients for treatment and to treat with a highly effective therapy. ACDx™ utilizes new imaging agents to radiolabel albumin. When used in combination with state-of-the art imaging techniques, the new agent facilitates detection of albumin uptake and distribution in the patient’s tumor. Since the LADR™ drug candidates are albumin-binding drugs, the Company believes response rates to their therapeutic compounds will be higher in patients who test positive with this personalized medicine companion diagnostic. In July 2018, Centurion filed a U.S. provisional patent application for ACDx™.

The LADR™ technology platform is a discovery engine combining CytRx’s expertise in linker chemistry and albumin biology to create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The Company has created a “toolbox” of linker technologies that have the ability to significantly increase the therapeutic index of ultra-high potency drugs (10-1,000 times more potent than traditional drugs) by controlling the release of the drug payloads and improving drug-like properties. After infusion, these ultra-high potency drug conjugates bind to circulating albumin for transport of the drug to the tumor. Subsequently, due to specific conditions within the tumor environment, the linkers are cleaved and release the anti-cancer drug payload.

Centurion’s current efforts are focused on two classes of ultra-high potency drug conjugates as well as its companion diagnostic. Its strategy across these programs is to generate additional pre-clinical data that will allow it to make informed decisions regarding the selection of one or both programs for moving into human clinical trials either independently or on a partnered basis.

The lead drug candidates that are currently being advanced by Centurion are the next generation drugs following the proof-of concept compound, aldoxorubicin, that CytRx had been developing. Aldoxorubicin is a conjugate of the commonly prescribed cytotoxic agent doxorubicin that binds to circulating albumin in the bloodstream and concentrates the drug at the site of the tumor. It has been tested in over 600 patients with various types of cancer.

Aldoxorubicin has received Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of soft tissue sarcoma (“STS”). ODD provides several benefits including seven years of market exclusivity after approval, certain R&D related tax credits, and protocol assistance by the FDA. European regulators granted aldoxorubicin Orphan designation for STS which confers ten years of market exclusivity among other benefits.

On July 27, 2017, CytRx entered into an exclusive worldwide license with NantCell, Inc. (“NantCell”), granting to NantCell the exclusive rights to develop, manufacture and commercialize aldoxorubicin in all indications. As a result, the Company is no longer directly working on development of aldoxorubicin. NantCell made a cash investment of $13 million in CytRx common stock at $6.60 per share (adjusted to reflect the reverse stock split effective November 1, 2017), a premium of 92% to the market price on that date. CytRx also issued NantCell a warrant to purchase up to 500,000 shares of common stock at $6.60 per share expiring on January 26, 2019. The Company is entitled to receive up to an aggregate of $343 million in potential milestone payments, contingent upon achievement of certain regulatory approvals and commercial milestones. CytRx is also entitled to receive ascending double-digit royalties for net sales for soft tissue sarcomas and mid to high single digit royalties for other indications. On October 3, 2017, CytRx entered into a Reimbursement Agreement with NantCell, Inc. whereby the Company agreed to reimburse it for payment obligations under certain of the contracts assigned as part of the licensing agreement, up to a maximum of $4.2 million plus one half of any amounts in excess thereof; the Company now anticipates the reimbursement will not exceed $3.4 million (see Note 3).

In the first half of 2018, CytRx announced that NantCell was expanding aldoxorubicin’s use by combining it with immunotherapies and cell based treatments, specifically in metastatic pancreatic cancer, in advanced squamous cell carcinoma of the head and neck or non-small cell lung cancer and in triple negative breast cancer.

In 2011, CytRx sold the rights to arimoclomol to Orphazyme A/S (formerly Orphazyme ApS) in exchange for a one-time, upfront payment and the right to receive up to a total of $120 million (USD) in milestone payments upon the achievement of certain pre-specified regulatory and business milestones, as well as royalty payments based on a specified percentage of any net sales of products derived from arimoclomol. Orphazyme is testing arimoclomol in three additional indications beyond ALS, including Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). CytRx received a milestone payment of $250,000 in September 2018. Orphazyme has reported that, if arimoclomol is approved for NPC by the EMA and/or FDA, Orphazyme intends to commercialize arimoclomol for the treatment of NPC during 2020. In such event, CytRx will be entitled to a milestone payment of $4 million upon EMA approval and $6 million upon FDA approval, along with royalties and potential additional milestones.

The accompanying condensed consolidated financial statements at September 30, 2018 and for the three-month and nine-month periods ended September 30, 2018 and 2017, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2017 have been derived from our audited financial statements as of that date.

The consolidated financial statements included herein have been prepared by us pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The consolidated financial statements should be read in conjunction with the Company’s audited financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2017.

2.	Foreign Currency Remeasurement

The U.S. dollar has been determined to be the functional currency for the net assets of our German laboratory facility. The transactions are recorded in the local currencies and are remeasured at each reporting date using the historical rates for nonmonetary assets and liabilities and current exchange rates for monetary assets and liabilities at the balance sheet date. Exchange gains and losses from the remeasurement of monetary assets and liabilities are recognized in other income (loss). The Company recognized a loss of approximately $1,300 and $7,600, respectively, for the three-month and nine-month periods ended September 30, 2018 and a loss of approximately $2,000 and $15,000, respectively, for the three and nine-month periods ended September 30, 2017, respectively. The Company does not engage in currency hedging transactions.

3.	Recently Adopted Accounting Pronouncement

On January 1, 2018 CytRx adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (“ASC 606”) using the modified retrospective method for contracts that were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. The cumulative effect of initially applying ASC 606 was an adjustment to decrease the opening balance of Accumulated Deficit by $6.7 million as of January 1, 2018.

The guidance provides for a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers.

Under the new standard the NantCell Licensing Agreement, which was determined to be a functional license agreement, as the underlying intellectual property had standalone functionality, was recognizable in 2017 when NantCell obtained the right to use the intellectual property. The subsequent Reimbursement Agreement was determined to be a contract modification that introduced variable contra revenue for the Company’s reimbursement obligations. In accordance with ASC 606, management estimated its obligations under the Reimbursement Agreement to be $3.2 million which is recognized as a contract liability at the time of revenue recognition. These costs were previously recognized as research and development expense in 2017 in accordance with prior accounting standards. This contract liability was reduced to $0.3 million as of January 1, 2018 as a result of costs incurred under the Reimbursement Agreement.

Additionally, CytRx is eligible to receive tiered high single to low double-digit royalties on product sales. The royalty term is determined on a licensed-product-by-licensed-product and country-by-country basis and begins on the first commercial sale of a licensed product in a country and ends on the expiration of the last to expire of specified patents or regulatory exclusivity covering such licensed product in such country or, with a customary royalty reduction, ten years after the first commercial sale if there is no such exclusivity. These revenues will be recognized when earned.

In January 2016, the FASB issued Accounting Standards Update 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). ASU 2016-01 eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet. The standard also clarifies the need to evaluate a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with our other deferred tax assets. The update 2016-01 is effective for annual reporting periods beginning after December 15, 2017. The adoption of this standard did not have a material impact on our financial statements.

4.	Recent Accounting Pronouncements

In June 2018, the FASB issued ASU 2018-07: Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year, early adoption is permitted but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact this new guidance will have on its financial statements and related disclosures.

In February 2018, the FASB issued a new standard that would permit entities to make a one time reclassification from accumulated other comprehensive income (AOCI) to retained earnings for the stranded tax effects resulting from the newly enacted corporate tax rates under the Tax Cuts and Jobs Act (the “Act”), effective for the year ended December 31, 2017. The amount of the reclassification is calculated on the basis of the difference between the historical tax rate and newly enacted tax rate. The standard is effective for interim and annual periods beginning after December 15, 2018 with early adoption permitted. We are currently assessing the impact of this standard on our financial condition and results of operations.

In January 2017, the FASB issued an ASU entitled “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.” The objective of the ASU is to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. We do not believe that the adoption of this guidance will have a material impact on our financial statements

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. This ASU retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model in Topic 842, the effect of leases in a statement of operations and a statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier adoption is permitted. The Company is currently evaluating the impact this new guidance will have on its financial statements and related disclosures.

5.	Term Loan

On February 5, 2016, we entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (“HTGC”), as administrative agent and lender, and Hercules Technology III, L.P., as lender (“Hercules”), pursuant to which the lenders made term loans to us on February 8, 2016 in the aggregate principal amount of $25 million (the “Term Loans”).

The Term Loans bear interest at the daily variable rate per annum equal to 6.0% plus the prime rate, or 11.0%, whichever is greater. CytRx was required to make interest-only payments on the Term Loans through February 28, 2017, and beginning on March 1, 2017 blended equal monthly installments of principal amortization and accrued interest until the maturity date of the Term Loans on February 1, 2020. As security under their obligations, the Company issued to the lenders warrants to purchase a total of 105,691 shares of its common stock at an exercise price of $12.30. These warrants are classified as equity warrants with a fair value of $633,749. All outstanding principal and accrued interest on the term loans was paid in full on the maturity date of August 1, 2018.

As a result of the NantCell exclusive licensing transaction, on July 28, 2017, CytRx entered into a First Amendment to Loan and Security Agreement with Hercules to amend its existing long-term loan facility (the “Loan Agreement”). The amendment provided for payment, on July 28, 2017, of $5.0 million in outstanding principal and unpaid interest due under the Loan Agreement, plus a $100,000 prepayment charge, and for repayment, on or prior to September 30, 2017, of an additional $5.0 million outstanding principal and unpaid interest due under the Loan Agreement, plus a second $100,000 prepayment charge. CytRx also agreed to an updated schedule of monthly payments and a new maturity date of August 1, 2018. Pursuant to the amendment, a portion of the warrants (representing 80% of the total number of shares issuable upon exercise of the warrants) was amended to change the exercise price of that portion of the warrants from $12.30 per share to $4.62 per share, which was calculated based upon the 30-day volume-weighted average price of our common stock over the 30-day period beginning 15 days before the July 28, 2017 announcement of the NantCell license transaction. CytRx evaluated the amended debt agreement under ASC 470 and determined it to be a modification and that in accordance with accounting guidance for debt modifications, the incremental fair value of the repriced warrants of $77,000 and the $200,000 fee paid to the lender was recorded as additional loan discount to be recognized using the interest method over the remaining life of the loan.

	December 31, 2017
Term Loan Principal	$	9,986,362
End Fee Payable		1,771,250
Issuance Cost/Loan Discount		(1,157,817	)
Term Loan, Net	$	10,599,795

The interest expense on the loan for the three-month and nine-month periods ended September 30, 2018 was $363,086 and $1,715,733, respectively, as compared to $828,120 and $2,999,230 for comparative 2017 periods.

6.	Basic and Diluted Net Loss Per Common Share

Basic and diluted net loss per common share is computed based on the weighted-average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation of diluted net loss per common share where the effect would be anti-dilutive. Common share equivalents that could potentially dilute net loss per share in the future, and which were excluded from the computation of diluted loss per share, totaled 3.5 million shares for each of the three-month and nine-month periods ended September 30, 2018, and 6.5 million shares for each of the three-month and nine-month periods ended September 30, 2017.

7.	Warrant Liabilities

Liabilities measured at fair value on a recurring basis include warrant liabilities resulting from our equity financings. In accordance with ASC 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity (“ASC 815-40”), the warrant liabilities are recorded at fair value until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with the Company’s application of ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). The gain or loss resulting from the change in fair value is shown on the Condensed Statements of Operations as gain (loss) on warrant derivative liability. We recognized a gain of $0 and $3.8 million for the three-month periods ended September 30, 2018 and 2017, respectively, and a gain (loss) of $0.5 million and ($0.6 million) for the nine-month periods ended September 30, 2018 and 2017, respectively. The following reflects the weighted-average assumptions for each of the nine-month periods indicated:

	September 30, 2018		December 31, 2017
Risk-free interest rate		—		1.31	%
Expected dividend yield		—		0	%
Expected lives		—		0.8
Expected volatility		—		120.8	%
Warrants classified as liabilities (in shares)		—		2,834,246

Our computation of expected volatility is based on the historical daily volatility of our publicly traded stock. The dividend yield assumption of zero is based upon the fact that we have never paid cash dividends and presently have no intention to do so. The risk-free interest rate used for each warrant classified as a derivative is equal to the U.S. Treasury rates in effect at September 30 of each year presented. The expected lives are based on the remaining contractual lives of the related warrants at the valuation date.

On July 20, 2018, 2,834,246 warrants classified as liabilities expired.

8.	Stock Based Compensation

We have a 2000 Long-Term Incentive Plan, which expired on August 6, 2010. As of September 30, 2018, there were 28,897 shares subject to outstanding stock options under this plan. No further shares are available for future grant under this plan.

We also have a 2008 Stock Incentive Plan. As of September 30, 2018, there were approximately 2.7 million shares subject to outstanding stock options and approximately 0.8 million shares outstanding related to restricted stock grants.

We follow ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.

For stock options and stock warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50.

Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. As a result, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested.

The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Consolidated Statements of Operations:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2018		2017			2018		2017
Research and development — employee	$	28,683	$	(124,405	)	$	89,105	$	507,211
General and administrative — employee		243,673		479,330			799,832		1,348,815
Total employee stock-based compensation	$	272,356	$	354,925		$	888,937	$	1,856,026

Research and development — non-employee	$	—	$	11,600		$	—	$	11,600
General and administrative — non-employee		19,517		32,581			60,384		97,818
Total non-employee stock-based compensation	$	19,517	$	44,181		$	60,384	$	109,418

During the nine-month period ended September 30, 2018, we granted stock options to purchase 1,667 shares of our common stock at an average weighted exercise price of $1.89. During the nine-month period ended September 30, 2017, we granted stock options to purchase 35,000 shares of our common stock at a weighted average exercise price of $3.96. The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:

	Nine Months Ended September 30, 2018			Nine Months Ended September 30, 2017
Risk-free interest rate		2.42	%		2.32	%
Expected volatility		91.6	%		90.7	%
Expected lives (years)		6			6 to 10
Expected dividend yield		0.00	%		0.00	%

Our computation of expected volatility is based on the historical daily volatility of our publicly traded stock. We use historical information to compute expected lives. In the nine-month period ended September 30, 2018, the contractual term of the options granted was ten years. The dividend yield assumption of zero is based upon the fact we have never paid cash dividends and presently have no intention to do so. The risk-free interest rate used for each grant and issuance is equal to the U.S. Treasury rates in effect at the time of the grant and issuance for instruments with a similar expected life. On January 1, 2017, the Company adopted ASU 2016-09 and made a policy election to recognize forfeitures as they occur. The adoption of ASU 2016-09 did not have a material impact to the Company’s financial condition or results of operations. No amounts relating to stock-based compensation have been capitalized.

As of September 30, 2018, there remained approximately $0.7 million of unrecognized compensation expense related to unvested stock options granted to current and former employees, directors, to be recognized as expense over a weighted-average period of 0.82 years. Presented below is our stock option activity:

	Nine Months Ended September 30, 2018
	Number of Options (Employees)			Number of Options (Non-Employees)		Total Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2018		2,492,179			373,333		2,865,512		$	10.62
Granted		1,667			—		1,667		$	1.89
Exercised, Forfeited or Expired		(135,168	)		—		(135,168	)	$	9.42
Outstanding at September 30, 2018		2,358,678			373,333		2,732,011		$	10.67
Options exercisable at September 30, 2018		1,906,571			373,333		2,279,904		$	12.22

The following table summarizes significant ranges of outstanding stock options under our plans at September 30, 2018:

Range of Exercise Prices	Total Number of Options		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price		Total Number of Options Exercisable		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price
$1.75 - $5.00		1,271,809		8.83	$	2.14		849,696		8.80	$	2.19
$5.01 – $11.00		178,335		4.19	$	10.98		178,335		4.19	$	10.98
$11.01 – $15.00		766,292		6.44	$	13.91		736,715		6.41	$	13.88
$15.01 – $98.28		515,575		4.84	$	26.80		515,158		4.84	$	26.81
		2,732,011		7.10	$	10.67		2,279,904		6.77	$	12.22

There was no aggregate intrinsic value to the outstanding options and vested options as of September 30, 2018.

There were 734,864 and 3,980,781 warrants outstanding at September 30, 2018 and December 31, 2017, respectively at a weighted-average exercise price of $7.90 and $4.26, respectively.

Restricted Stock

In December 2017, the Company granted to its Chairman and Chief Executive Officer, 387,597 shares of restricted common stock, pursuant to the 2008 Plan. This restricted stock vests in equal annual instalments over three years. The fair value of the restricted stock is based on the market price of the Company’s shares on the grant date less the par value received as consideration. The fair value of the restricted stock on the grant date was $679,000. In December 2016, the Company granted to its Chairman and Chief Executive Officer, 387,597 shares of restricted common stock, pursuant to the 2008 Plan. This restricted stock vests in equal annual instalments over three years. The fair value of the restricted stock is based on the market price of the Company’s shares on the grant date less the par value received as consideration. The fair value of the restricted stock on the grant date was $1,000,000. The Company recorded an employee stock-based compensation expense for restricted stock of $140,827 and $417,889 respectively, for the three and nine-month periods ended September 30, 2018 as compared to $83,943 and $249,089 respectively, for the three and nine-month periods ended September 30, 2017.

9.	Fair Value Measurements

Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows:

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at September 30, 2018 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)		Level I				Level II				Level III				Total
Cash equivalents		$	21,462			$	—			$	—			$	21,462

The following table summarizes fair value measurements by level at December 31, 2017 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	35,834	$	—	$	—		$	35,834
Warrant liabilities		—		—		(527	)		(527	)

Liabilities measured at market value on a recurring basis include warrant liabilities resulting from recent debt and equity financings. In accordance with ASC 815-40, the warrant liabilities are marked to market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with our application of ASC 505-50. The $0.5 million decrease in fair value of the warrant liabilities is due to the expiry of the warrants (see Note 7).

We consider carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.

Our non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. Our non-financial assets were not material at September 30, 2018 or 2017.

10.	Liquidity and Capital Resources

At September 30, 2018, the Company had cash and cash equivalents of approximately $24.7 million. Management believes that our current cash and cash equivalents will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2018 and the first ten months of 2019 of approximately $9.2 million, which includes approximately $0.6 million for our contract liabilities, approximately $1.7 million for the development of a novel companion diagnostic and the preclinical development of the new drug candidates at Centurion BioPharma, approximately $6.9 million for other general and administrative expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.

If NantCell and Orphayzme obtain marketing approval and successfully commercialize aldoxorubicin and arimoclomol, respectively, we anticipate it could take several years, for them to generate significant recurring revenue. We will be dependent on future financing and possible other strategic partnerships until such time, if ever, as they can generate significant recurring revenue. We have no commitments from third parties to provide any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourselves, or seek to sell some or all of our assets or merge with or be acquired by another company.

11.

Equity Transactions

On May 15, 2018, we issued 5.6 million shares of our common stock in a public offering and raised net proceeds of approximately $6.5 million.

12.

Income Taxes

At December 31, 2017, we had federal and state net operating loss carryforwards as of $310.6 million and $285.0 million, respectively, available to offset against future taxable income, which expire in 2018 through 2037, of which $236.2 million and $285.0 million, respectively, are not subject to limitation under Section 382 of the Internal Revenue Code.

13.

Commitments and contingencies

Commitments

We have an agreement with Vergell Medical (formerly KTB Tumorforschungs GmbH, or KTB) (“Vergell”) for the Company’s exclusive license of patent rights held by Vergell for the worldwide development and commercialization of aldoxorubicin. Under the agreement, we must make payments to Vergell in the aggregate of $7.5 million upon meeting clinical and regulatory milestones up to and including the product’s second final marketing approval. We also have agreed to pay:

		●	commercially reasonable royalties based on a percentage of net sales (as defined in the agreement);

		●	a percentage of non-royalty sub-licensing income (as defined in the agreement); and

		●	milestones of $1 million for each additional final marketing approval that we obtain.

In the event that we must pay a third party in order to exercise our right to the intellectual property under the agreement, we will deduct a percentage of those payments from the royalties due Vergell, up to an agreed upon cap.

Contingencies

We applied the disclosure provisions of ASC 460, Guarantees (“ASC 460”) to our agreements that contain guarantees or indemnities by us. We provide (i) indemnifications of varying scope and size to certain investors and other parties for certain losses suffered or incurred by the indemnified party in connection with various types of third-party claims; and (ii) indemnifications of varying scope and size to officers and directors against third party claims arising from the services they provide to us.

Shareholder Derivative Actions in Delaware. There are two competing derivative complaints pending in the Delaware Court of Chancery alleging claims related to our alleged retention of DreamTeamGroup and MissionIR. On December 14, 2015, a shareholder derivative complaint, captioned Niedermeyer et al. v. Kriegsman et al., C.A. No. 11800, was filed against certain of our officers and directors, for which a second amended complaint was filed on October 12, 2016. On September 6, 2016, one of the plaintiffs in the California litigation (discussed above) effectively refiled his complaint in the Delaware Court of Chancery, with the case captioned Taylor v. Kriegsman, C.A. No. 12720. Following competing motions for appointment of a lead plaintiff and lead counsel, on February 22, 2017, the Court of Chancery appointed Niedermeyer et al.as lead plaintiffs in the complaint. On May 3, 2017, the parties entered into negotiations with a mediator and on June 2, 2017, the parties entered into a Memorandum of Understanding (“MOU”) to settle the entire action. On June 15, 2017, the MOU was submitted to the Court and the parties are now seeking Court approval. The Stipulation of Settlement was filed with the Court on January 22, 2018, which was preliminarily approved by the Court. A Final Approval hearing and hearing on the application for an attorney fee award was held on April 19, 2018. On May 10, 2018, the Court approved the settlement and a determination of attorneys’ fees was made. A third party appeal was made by an objecting shareholder regarding the attorney fee award only, which is currently pending before the Delaware Supreme Court. The appeal is fully briefed and the Court has indicated it will decide the appeal without oral argument. The Company was not involved in the briefing, but will continue to monitor until final resolution.

Class Action in California. On July 25 and 29, 2016, nearly identical class action complaints were filed in the U.S. District Court for the Central District of California, titled Crihfield v. CytRx Corp., et al., Case No. 2:16-cv-05519 and Dorce v. CytRx Corp., Case No. 2:16-cv-05666 alleging that we and certain of our officers violated the Securities Exchange Act of 1934 by allegedly making materially false and/or misleading statements, and/or failing to disclose material adverse facts to the effect that the clinical hold placed on the Phase 3 trial of aldoxorubicin for STS would prevent sufficient follow-up for patients involved in the study, thus requiring further analysis, which could cause the trial’s results and/or FDA approval to be materially adversely affected or delayed. The plaintiffs allege that such wrongful acts and omissions caused significant losses and damages to a class of persons and entities that acquired our securities between November 18, 2014 and July 11, 2016, and seek an award of compensatory damages, costs and expenses, including counsel and expert fees, and such other and further relief as the Court may deem just and proper. On October 26, 2016, the Court entered an Order consolidating the actions titled In re: CytRx Corporation Securities Litigation, Master File No. 16-cv-05519-SJO and appointing a Lead Plaintiff and Lead Counsel. Following the filing of a first amended complaint on January 13, 2017, on March 14, 2017 we and the individual defendants filed a Motion to Dismiss. Plaintiff filed an Opposition thereto on April 28, 2017. We and the individual defendants filed a Reply on May 30, 2017 and the matter was heard by the Court on June 12, 2017. On June 14, 2017, the Court issued an Order granting the Motion to Dismiss with leave to amend. Plaintiff filed a Second Amended Complaint and the Individual Defendants filed a renewed Motion to Dismiss. Plaintiff filed an Opposition thereto on July 24, 2017. We and the Individual Defendants filed a Reply on July 31, 2017. On August 14, 2017, the Court issued an Order granting in part and denying in part the motion to dismiss. On September 18, 2017, the Court issued an Order setting a schedule for the case. On January 30, 2018, the parties entered into negotiations with a mediator and on February 1, 2018, the parties entered into a confidential Term Sheet to settle the Class Action. On February 7, 2018, the Court stayed the action for all purposes until May 2, 2018, to provide the parties sufficient time to prepare and submit a stipulation of settlement. On May 4, 2018, the Motion for Preliminary Approval of Settlement was filed. On June 20, 2018 the Court granted the Motion for Preliminary Approval of Settlement. A Final Approval hearing was held on September 17, 2018, after which the Court issued an order approving the settlement and thereafter issue a final judgment.

Shareholder Derivative Action in Delaware (Zyontz). On October 17, 2017, a shareholder derivative complaint was filed against certain current and former directors in the Delaware Court of Chancery, entitled Zyontz v. Kriegsman et al., Case No. 2017-0738-JRS. The complaint essentially sets forth the allegations pled in the federal securities class action in California, asserts a claim for breach of fiduciary duty, and seeks damages, fees and costs, and other and further relief as the Court may deem just and proper. On December 18, 2017, we and individual defendants filed a motion to dismiss for failure to make a demand on the Board and for failure to state a claim, and a motion to stay the proceedings pending resolution of the federal securities class action. On January 30, 2018, the parties participated in a mediation. On March 15, 2018, the parties executed a memorandum of understanding for a settlement, subject to shareholder notice and court approval. The Company also reached a settlement agreement with two potential objectors who had made shareholder demands. A final approval hearing on both settlements collectively is scheduled for December 10, 2018, at which time the Court will consider the motion to approve the settlements and the motions for attorneys’ fees and costs.

The Company intends to vigorously defend against the foregoing complaints. CytRx has directors’ and officers’ liability insurance, which is being utilized in the defense of these matters. The liability insurance may not cover all of the future liabilities the Company may incur in connection with the foregoing matters. These claims are subject to inherent uncertainties, and management’s view of these matters may change in the future.

The Company evaluates developments in legal proceedings and other matters on a quarterly basis. The Company records accruals for loss contingencies to the extent that the Company concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company has accrued $5.8 million of litigation settlement related to a Shareholder Class action, of which the entire amount is recorded as a receivable from the Company’s insurance carriers on its Consolidated Balance Sheet.

We evaluate developments in legal proceedings and other matters on a quarterly basis. If an unfavorable outcome becomes probable and reasonably estimable, we could incur charges that could have a material adverse impact on our financial condition and results of operations for the period in which the outcome becomes probable and reasonably estimable.

Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

All statements in this Quarterly Report, including statements in this section, other than statements of historical fact are forward-looking statements, including statements of our current views with respect to the recent developments regarding our business strategy, business plan and research and development activities, our future financial results, and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology industry, in general. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “potential” or “could” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements.

All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, the factors discussed in this section and under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, which should be reviewed carefully. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. Please consider our forward-looking statements in light of those risks as you read this Quarterly Report. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Overview

During 2017, CytRx’s discovery laboratory synthesized and tested over 75 rationally designed drug conjugates with highly potent payloads, culminating in the creation of two distinct classes of compounds. To date, four lead candidates have been selected based on in vitro and animal preclinical studies, stability, and manufacturing feasibility. Additional animal efficacy and toxicology testing of these lead candidates is underway.

On June 1, 2018, CytRx launched Centurion BioPharma Corporation (“Centurion”), a private wholly owned subsidiary, and transferred all of its assets, liabilities and personnel associated with the laboratory operations in Freiburg, Germany. Centurion is focused on the development of personalized medicine to transform solid tumor treatment. In connection with said transfer, the Company and Centurion entered into a Management Services Agreement whereby the Company agreed to render advisory, consulting, financial and administrative services to Centurion, for which Centurion shall reimburse the Company for the cost of such services plus a 5% service charge. The Management Services Agreement may be terminated by either party at any time. Centurion is focused on the development of personalized medicine for solid tumor treatment.

There are two key elements to Centurion’s strategy:

	3.	A novel companion diagnostic, ACDx™ (albumin companion diagnostic), developed to identify patients with cancer who are most likely to benefit from treatment with Centurion’s lead assets.

	4.	Development of its four albumin binding, linker activated drug release (LADR) oncology candidates.

Centurion’s current efforts are focused on two classes of ultra-high potency drug conjugates. Its strategy across these programs is to generate additional pre-clinical data that will allow them to make informed decisions regarding the selection of one or both programs for moving into human clinical trials either independently or on a partnered basis.

Currently, the Company’s research and development activities are conducted through its wholly-owned subsidiary, Centurion BioPharma Corporation. For this reason, and the transfer of the aldoxorubicin program to NantCell, operating expenses are expected to be significantly lower in the near future. Therefore, period to period comparisons should not be relied upon as predictive of the results in future periods.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, impairment of long-lived assets, including finite-lived intangible assets, research and development expenses and clinical trial expenses and stock-based compensation expense.

We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our significant accounting policies are summarized in Note 2 to our financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2017. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.

Revenue Recognition

Revenue consists of license fees from strategic alliances with pharmaceutical companies, as well as grant revenues. Grant revenues consist of government and private grants.

In May 2014, the FASB issued a comprehensive new standard which amends revenue recognition principles. We adopted the new standard on January 1, 2018 by applying the modified retrospective method to all contracts that were not completed as of that date. Under the new guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. We only apply the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, we assess the goods or services promised within each contract, and determines those that are performance obligations. Revenue is recognized when each distinct performance obligation is satisfied. CytRx will include the variable consideration related to milestones from strategic alliances if it no longer considers it probable that including these payments in the transaction price would not result in the reversal of cumulative revenue recognized.

Research and Development Expenses

Research and development expenses consist of direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred. Costs of technology developed for use in our products are expensed as incurred until technological feasibility has been established.

Stock-Based Compensation

Our stock-based employee compensation plans are described in Note 8 of the Notes to Condensed Financial Statements included in this Quarterly Report. We follow ASC 718, Compensation-Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.

For stock options and warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”).

Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options is determined using the Black-Scholes option-pricing model, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted or issued to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested.

The fair value of each stock option and warrant is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option-pricing model, based on an expected forfeiture rate that is adjusted for our actual experience. If our Black-Scholes option-pricing model assumptions or our actual or estimated forfeiture rate are different in the future, it could materially affect our compensation expense recorded in future periods.

Impairment of Long-Lived Assets

We review long-lived assets, including finite-lived intangible assets, for impairment on an annual basis as of December 31, or on an interim basis if an event occurs that might reduce the fair value of such assets below their carrying values. An impairment loss would be recognized based on the difference between the carrying value of the asset and its estimated fair value, which would be determined based on either discounted future cash flows or other appropriate fair value methods. If our estimates used in the determination of either discounted future cash flows or other appropriate fair value methods are not accurate as compared to actual future results, we may be required to record an impairment charge.

Net Income (Loss) per Share

Basic and diluted net loss per common share is computed using the weighted-average number of common shares outstanding. Potentially dilutive stock options and warrants to purchase 3.5 million shares for each of the three-month and nine-month periods ended September 30, 2018, and 6.5 million shares for each of the three-month and nine-month periods ended September 30, 2017, were excluded from the computation of diluted net loss per share, because the effect would be anti-dilutive.

Warrant Liabilities

Liabilities measured at fair value on a recurring basis include warrant liabilities resulting from the Company’s July 2016 equity financings. In accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company’s Own Stock (“ASC 815-40”), the warrant liabilities are being marked to fair value each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with CytRx’s application of ASC 505-50. The gain or loss resulting from the fair value calculation is shown on the Statements of Operations as gain (loss) on warrant liabilities. There were no remaining warrant liabilities at September 30, 2018.

Liquidity and Capital Resources

We have relied primarily upon proceeds from sales of our equity securities and the exercise of options and warrants, and to a much lesser extent upon payments from our strategic partners and licensees, to generate funds needed to finance our business and operation.

At September 30, 2018, the Company had cash and cash equivalents of approximately $24.7 million. Management believes that our current cash and cash equivalents will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2018 and the first ten months of 2019 of approximately $9.2 million, which includes approximately $0.6 million for our contract liabilities, approximately $1.7 million for the development of a novel companion diagnostic and the pre-clinical development of the new drug candidates at Centurion BioPharma Corporation, approximately $6.9 million for other general and administrative expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.

If NantCell obtains marketing approval and successfully commercializes aldoxorubicin, we anticipate it could take several years, for it to generate significant recurring revenue. We will be dependent on future financing and possible other strategic partnerships until such time, if ever, as it can generate significant recurring revenue. We have no commitments from third parties to provide any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourself, or seek to sell some or all of our assets or merge with or be acquired by another company.

We recorded a net loss in the nine-months ended September 30, 2018 of $10.4 million as compared to a net loss in the nine-months ended September 30, 2017 of $30.5 million, or a decrease of $20.1 million. This was due primarily to a decrease in our research and development expenditures in the current nine-month period of $14.5 million as compared to the comparative 2017 period, as our pivotal clinical trial program was licensed to NantCell in July 2017; we also realized a decrease of $3.0 million in general and administrative expenditures, a difference in gain (loss) on the warrant derivative liability of $1.1 million, and a decrease in interest on the term loan of $1.3 million, due to the two balloon principal payments made in the third quarter of 2017.

We made capital expenditures of $11,000 in the nine-month period ended September 30, 2018 as compared to approximately $135,000 in the comparable 2017 period. We do not expect any significant capital spending during the next 12 months.

We received a net amount of $6.5 million from the proceeds of a public offering in May 2018 as compared to a net amount of $14.0 million from the proceeds of a public offering in May 2017. There were no receipts from the exercise of warrants in the current period as compared to $3.2 million of warrant and stock option exercise net proceeds in the comparative 2017 period. We also made principal payments on our Term Loan of $10.0 million and an end fee payment of $1.8 million in the current period as compared to $14 million in principal payments in the comparative period in 2017.

We continue to evaluate potential future sources of capital, as we do not currently have commitments from any third parties to provide us with additional capital. The results of our technology licensing efforts and the actual proceeds of any fund-raising activities will determine our ongoing ability to operate as a going concern. Our ability to obtain future financings through joint ventures, product licensing arrangements, royalty sales, equity financings, grants or otherwise is subject to market conditions, the ability of our partner to commercialize aldoxorubicin and our ability to identify parties that are willing and able to enter into such arrangements related to our drug development efforts in our German lab on terms that are satisfactory to us. Depending upon the outcome of our fundraising efforts, the accompanying financial information may not necessarily be indicative of our future financial condition.

As a development company that is primarily engaged in research and development activities, we expect to incur significant losses and negative cash flow from operating activities for the foreseeable future. There can be no assurance that we will be able to generate revenues from our product candidates and become profitable. Even if we become profitable, we may not be able to sustain that profitability.

Results of Operations

We recorded a net loss of approximately $3.3 million and $10.4 million for the three-month and nine-month periods ended September 30, 2018, respectively, as compared to a net loss of approximately $5.1 million and $30.5 million for the three-month and nine-month periods ended September 30, 2017, respectively. The decrease of $1.8 million in our net loss during the current three-month period resulted primarily from a reduction of $3.8 million in the expenditures related to the aldoxorubicin program, which was licensed to NantCell in July 2017, a decrease in general and administrative expenses of $1.0 million, due primarily to a reduction in legal fees, a decrease in interest expenses of $0.5 million, offset by a difference in gain on the warrant derivative liability of $3.8 million.

We recognized $250,000 of licensing revenue in the three and nine-month periods ended September 30, 2018 and none in the comparative 2017 periods. All future licensing fees under our current licensing agreements are dependent upon successful development milestones being achieved by the licensors. During the remainder of 2018, we do not anticipate receiving any significant licensing fees.

Research and Development

	Three-Month Period Ended September 30,					Nine-Month Period Ended September 30,
	2018		2017			2018		2017
	(In thousands)					(In thousands)
Research and development expenses	$	750	$	4,729		$	2,706	$	16,683
Employee stock option expense		29		(112	)		89		519
Depreciation and amortization		131		138			392		473
	$	910	$	4,755		$	3,187	$	17,675

Research expenses are those incurred by us in the discovery of new information that will assist us in the creation and the development of new drugs or treatments. Development expenses are those incurred by us in our efforts to commercialize the findings generated through our research efforts. Our research and development expenses, excluding stock option expense, non-cash expenses and depreciation and amortization, were $0.8 million and $2.7 million for the three-month and nine-month periods ended September 30, 2018, respectively, and $4.7 million and $16.7 million for the three-month and nine-month periods ended September 30, 2017, respectively.

During the three-month period ended September 30, 2018, the Freiburg Germany drug discovery program expenses were $0.7 million. In the 2017 comparative period, $3.7 million of research and development expenses related to the aldoxorubicin program and its clinical support and the Freiburg drug discovery program expenses were $1.0 million. We recorded approximately $29,000 and $89,000 of employee stock option expense in the three-month and nine-month periods ended September 30, 2018, as compared to ($0.1) million and $0.5 million for the same periods in 2017, respectively.

General and Administrative Expenses

	Three-Month Period Ended September 30,				Nine-Month Period Ended September 30,
	2018		2017		2018		2017
	(In thousands)				(In thousands)
General and administrative expenses	$	1,952	$	2,817	$	5,220	$	7,819
Non-cash general and administrative expenses		20		33		60		98
Employee stock option expense		384		563		1,218		1,598
Depreciation and amortization		5		6		16		20
	$	2,361	$	3,419	$	6,514	$	9,535

General and administrative expenses include all administrative salaries and general corporate expenses, including legal expenses. Our general and administrative expenses, excluding stock option expense, non-cash expenses and depreciation and amortization, were $2.0 million and $5.2 million for the three and nine-month periods ended September 30, 2018, respectively, and $2.8 million and $7.8 million, respectively, for the same periods in 2017.

Employee stock option expense relates to options granted to retain and compensate directors, officers and other employees. We recorded, in total, approximately $0.4 million and $1.2 million of employee stock option expense in the three-month and nine-month periods ended September 30, 2018, respectively, as compared to $0.6 million and $1.6 million, respectively, for the same periods in 2017. We recorded approximately $20,000 and $60,000 of non-employee stock option expense in the three-month and nine-month periods, ended September 30, 2018, respectively, and $33,000 and $98,000 for the comparative 2017 periods.

Depreciation and Amortization

Depreciation expense reflects the depreciation of our equipment and furnishings.

Interest Income and Expense

Interest income was approximately $93,000 and $269,000 for the three-month and nine-month periods ended September 30, 2018, respectively, as compared to $120,000 and $271,000, respectively, for the same periods in 2017. This decrease was related to the decrease in cash and cash equivalents and short term investments.

Interest expense was approximately $0.4 million and $1.7 million for the three-month and nine-month periods ended September 30, 2018, respectively as compared to $0.8 million and $3.0 million for the comparative 2017 periods.

Item 3. — Quantitative and Qualitative Disclosures About Market Risk

Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because a significant portion of our investments are in short-term debt securities issued by the U.S. government and institutional money market funds. The primary objective of our investment activities is to preserve principal. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any speculative or hedging derivative financial instruments or foreign currency instruments. If interest rates had varied by 10% in the three-month period ended September 30, 2018, it would not have had a material effect on our results of operations or cash flows for that period.

Item 4. — Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act Rule 13a-15(e)) as of the end of the quarterly period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.

Changes in Controls over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended September 30, 2018 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We continually seek to assure that all of our controls and procedures are adequate and effective. Any failure to implement and maintain improvements in the controls over our financial reporting could cause us to fail to meet our reporting obligations under the SEC’s rules and regulations. Any failure to improve our internal controls to address the weakness we have identified could also cause investors to lose confidence in our reported financial information, which could have a negative impact on the trading price of our common stock.

PART II — OTHER INFORMATION

Item 1. — Legal Proceedings

The disclosure set forth in Note 13 to our consolidated financial statements is herein incorporated by reference.

Item 1A. Risk Factors

You should carefully consider and evaluate the information in this Quarterly Report and the risk factors set forth under the caption “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the “Form 10-K”), which was filed with the SEC on March 16, 2018. The risk factors associated with our business have not materially changed compared to the risk factors disclosed in the Form 10-K.

Item 6. — Exhibits

The exhibits listed in the accompanying Index to Exhibits are filed as part of this Quarterly Report and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CytRx Corporation

Date: November 2, 2018	By:	/s/ JOHN Y. CALOZ
		John Y. Caloz
		Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number		Description
31.1		Certification of Chief Executive Officer Pursuant to 17 CFR 240.13a-14(a)
31.2		Certification of Chief Financial Officer Pursuant to 17 CFR 240.13a-14(a)
32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Schema Document
101.CAL		XBRL Calculation Linkbase Document
101.DEF		XBRL Definition Linkbase Document
101.LAB		XBRL Label Linkbase Document
101.PRE		XBRL Presentation Linkbase Document

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATIONS

I, Steven A. Kriegsman, Chairman and Chief Executive Officer of CytRx Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CytRx Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules713a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the periods covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 2, 2018	By:	/s/ STEVEN A. KRIEGSMAN
		Steven A. Kriegsman
		Chairman and Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATIONS

I, John Y. Caloz, Chief Financial Officer of CytRx Corporation, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CytRx Corporation;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 2, 2018	By:	/s/ JOHN Y. CALOZ
		John Y. Caloz
		Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CytRx Corporation (the “Company”) hereby certifies based on his knowledge that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in the Report.

Date: November 2, 2018	By:	/s/ STEVEN A. KRIEGSMAN
		Steven A. Kriegsman
		Chairman and Chief Executive Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (Section 906), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to CytRx Corporation and will be retained by CytRx Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

The foregoing certification is being furnished to the Securities and Exchange Commission as an Exhibit to the Form 10-Q and shall not be considered filed as part of the Form 10-Q.

EX-32.2 5 ex32-2.htm

Exhibit 32.2

Certification of Chief Financial Officer

Date: November 2, 2018	By:	/s/ JOHN Y. CALOZ
		John Y. Caloz
		Chief Financial Officer

The foregoing certification is being furnished to the Securities and Exchange Commission as an Exhibit to the Form 10-Q and shall not be considered filed as part of the Form 10-Q.

EX-101.INS 6 cytr-20180930.xml XBRL INSTANCE FILE 0000799698 2018-01-01 2018-09-30 0000799698 2018-09-30 0000799698 2017-12-31 0000799698 CYTR:SeriesAJuniorParticipatingPreferredStockMember 2018-09-30 0000799698 CYTR:SeriesAJuniorParticipatingPreferredStockMember 2017-12-31 0000799698 2017-01-01 2017-09-30 0000799698 2016-12-31 0000799698 2017-09-30 0000799698 2017-07-27 0000799698 2017-07-25 2017-07-27 0000799698 CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2016-02-07 2016-02-08 0000799698 CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:PrimeRateMember 2016-02-07 2016-02-08 0000799698 CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2018-01-01 2018-09-30 0000799698 CYTR:LoanAgreementMember CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2017-07-26 2017-07-28 0000799698 CYTR:LoanAgreementMember CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2017-07-29 2017-09-30 0000799698 CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2018-09-30 0000799698 us-gaap:WarrantMember 2018-01-01 2018-09-30 0000799698 us-gaap:WarrantMember 2018-09-30 0000799698 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0000799698 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000799698 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0000799698 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000799698 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000799698 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-09-30 0000799698 CYTR:OtherGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0000799698 CYTR:ContractLiabilitiesMember 2018-01-01 2018-09-30 0000799698 us-gaap:LatestTaxYearMember 2017-01-01 2017-12-31 0000799698 us-gaap:EarliestTaxYearMember 2017-01-01 2017-12-31 0000799698 us-gaap:StateAndLocalJurisdictionMember 2017-12-31 0000799698 us-gaap:DomesticCountryMember 2017-12-31 0000799698 us-gaap:EmployeeStockOptionMember CYTR:ExercisePriceRangeTwoMember 2018-01-01 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:ExercisePriceRangeFourMember 2018-01-01 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:ExercisePriceRangeOneMember 2018-01-01 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:ExercisePriceRangeThreeMember 2018-01-01 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:ExercisePriceRangeFourMember 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:ExercisePriceRangeOneMember 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:ExercisePriceRangeThreeMember 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:ExercisePriceRangeTwoMember 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:EmployeesMember 2018-01-01 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:NonEmployeesMember 2018-01-01 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:EmployeesMember 2017-12-31 0000799698 us-gaap:EmployeeStockOptionMember CYTR:EmployeesMember 2018-09-30 0000799698 us-gaap:EmployeeStockOptionMember CYTR:NonEmployeesMember 2017-12-31 0000799698 us-gaap:EmployeeStockOptionMember CYTR:NonEmployeesMember 2018-09-30 0000799698 CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2018-01-01 2018-09-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2018-01-01 2018-09-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2018-01-01 2018-09-30 0000799698 CYTR:EmployeesMember CYTR:StockOptionsAndWarrantsMember 2018-01-01 2018-09-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2018-01-01 2018-09-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2018-01-01 2018-09-30 0000799698 CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2017-01-01 2017-09-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2017-01-01 2017-09-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember CYTR:EmployeesMember CYTR:StockOptionsAndWarrantsMember 2017-01-01 2017-09-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2017-01-01 2017-09-30 0000799698 CYTR:EmployeesMember CYTR:StockOptionsAndWarrantsMember 2017-01-01 2017-09-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2017-01-01 2017-09-30 0000799698 CYTR:LongTermIncentivePlanMember 2018-01-01 2018-09-30 0000799698 CYTR:LongTermIncentivePlanMember 2018-09-30 0000799698 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0000799698 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0000799698 CYTR:StockIncentivePlanMember 2018-09-30 0000799698 CYTR:StockIncentivePlanMember us-gaap:RestrictedStockMember 2018-09-30 0000799698 us-gaap:WarrantMember 2017-12-31 0000799698 us-gaap:PreferredStockMember 2018-09-30 0000799698 us-gaap:PreferredStockMember 2017-12-31 0000799698 2018-07-01 2018-09-30 0000799698 2017-07-01 2017-09-30 0000799698 2018-05-01 2018-05-15 0000799698 CYTR:CenturionBioPharmaCorporationMember 2018-01-01 2018-09-30 0000799698 CYTR:NantCellIncMember CYTR:ReimbursementAgreementMember srt:MaximumMember 2017-10-02 2017-10-03 0000799698 us-gaap:WarrantMember 2018-07-01 2018-09-30 0000799698 us-gaap:WarrantMember 2017-07-01 2017-09-30 0000799698 us-gaap:WarrantMember 2018-01-01 2018-09-30 0000799698 us-gaap:WarrantMember 2017-01-01 2017-09-30 0000799698 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0000799698 CYTR:CurrentAndFormerEmployeesDirectorsMember 2018-09-30 0000799698 CYTR:CurrentAndFormerEmployeesDirectorsMember 2018-01-01 2018-09-30 0000799698 CYTR:StockIncentivePlanMember us-gaap:RestrictedStockMember us-gaap:ChiefExecutiveOfficerMember 2017-12-01 2017-12-31 0000799698 CYTR:StockIncentivePlanMember us-gaap:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2016-12-01 2016-12-31 0000799698 us-gaap:RestrictedStockMember 2018-07-01 2018-09-30 0000799698 us-gaap:RestrictedStockMember 2017-07-01 2017-09-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2018-07-01 2018-09-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2017-07-01 2017-09-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2018-07-01 2018-09-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2017-07-01 2017-09-30 0000799698 CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2018-07-01 2018-09-30 0000799698 CYTR:StockOptionsAndWarrantsMember CYTR:EmployeesMember 2017-07-01 2017-09-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2018-07-01 2018-09-30 0000799698 us-gaap:ResearchAndDevelopmentExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2017-07-01 2017-09-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2018-07-01 2018-09-30 0000799698 us-gaap:GeneralAndAdministrativeExpenseMember CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2017-07-01 2017-09-30 0000799698 CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2018-07-01 2018-09-30 0000799698 CYTR:StockOptionsAndWarrantsMember CYTR:NonEmployeesMember 2017-07-01 2017-09-30 0000799698 2018-06-01 0000799698 2018-11-02 0000799698 CYTR:OrphazymeMember 2011-01-01 2011-12-31 0000799698 2018-09-01 2018-09-30 0000799698 CYTR:EMAMember 2018-01-01 2018-09-30 0000799698 CYTR:FDAMember 2018-01-01 2018-09-30 0000799698 us-gaap:WarrantMember 2017-01-01 2017-12-31 0000799698 srt:MinimumMember 2017-01-01 2017-09-30 0000799698 srt:MaximumMember 2017-01-01 2017-09-30 0000799698 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-02 0000799698 us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-12-31 0000799698 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member us-gaap:AccountingStandardsUpdate201409Member 2018-01-02 0000799698 CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember 2016-02-08 0000799698 CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:WarrantMember 2016-02-08 0000799698 CYTR:HerculesTechnologyGrowthCapitalIncAndHerculesTechnologyIIILPMember us-gaap:WarrantMember 2017-07-21 2017-07-28 0000799698 2018-07-19 2018-07-20 0000799698 us-gaap:StateAndLocalJurisdictionMember us-gaap:LatestTaxYearMember 2017-12-31 0000799698 us-gaap:DomesticCountryMember us-gaap:TaxYear2018Member 2017-12-31 0000799698 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CYTR:Integer CYTRX CORP 0000799698 10-Q 2018-09-30 false --12-31 Accelerated Filer Q3 33637501

0.01

833334

4167

650

0.001

41666667

33637501

28037501

33637501

28037501

1000 1000

527025

-572209

3763855

3800000

500000

-600000

9986362

14000478

5000000

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 12pt Times New Roman, Times, Serif; text-align: justify">8.</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Stock Based Compensation</td></tr> </table>   We have a 2000 Long-Term Incentive Plan, which expired on August 6, 2010. As of September 30, 2018, there were 28,897 shares subject to outstanding stock options under this plan. No further shares are available for future grant under this plan.   We also have a 2008 Stock Incentive Plan. As of September 30, 2018, there were approximately 2.7 million shares subject to outstanding stock options and approximately 0.8 million shares outstanding related to restricted stock grants.   We follow ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.   For stock options and stock warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50.   Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. As a result, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested.   The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Consolidated Statements of Operations:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Research and development — employee</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">28,683</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(124,405</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">89,105</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">507,211</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative — employee</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">243,673</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">479,330</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">799,832</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,348,815</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total employee stock-based compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">272,356</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">354,925</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">888,937</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,856,026</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Research and development — non-employee</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">11,600</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">11,600</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative — non-employee</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19,517</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">32,581</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">60,384</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">97,818</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total non-employee stock-based compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">19,517</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">44,181</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">60,384</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">109,418</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   During the nine-month period ended September 30, 2018, we granted stock options to purchase 1,667 shares of our common stock at an average weighted exercise price of $1.89. During the nine-month period ended September 30, 2017, we granted stock options to purchase 35,000 shares of our common stock at a weighted average exercise price of $3.96. The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 25%; text-align: right">2.42</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 25%; text-align: right">2.32</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">91.6</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">90.7</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected lives (years)</td> <td> </td> <td> </td> <td style="text-align: right">6</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">	6 to 10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> </table>   Our computation of expected volatility is based on the historical daily volatility of our publicly traded stock. We use historical information to compute expected lives. In the nine-month period ended September 30, 2018, the contractual term of the options granted was ten years. The dividend yield assumption of zero is based upon the fact we have never paid cash dividends and presently have no intention to do so. The risk-free interest rate used for each grant and issuance is equal to the U.S. Treasury rates in effect at the time of the grant and issuance for instruments with a similar expected life. On January 1, 2017, the Company adopted ASU 2016-09 and made a policy election to recognize forfeitures as they occur. The adoption of ASU 2016-09 did not have a material impact to the Company’s financial condition or results of operations. No amounts relating to stock-based compensation have been capitalized.   As of September 30, 2018, there remained approximately $0.7 million of unrecognized compensation expense related to unvested stock options granted to current and former employees, directors, to be recognized as expense over a weighted-average period of 0.82 years. Presented below is our stock option activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options (Employees)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options (Non-Employees)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total Number of Options</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 32%">Outstanding at January 1, 2018</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">2,492,179</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">373,333</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">2,865,512</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">10.62</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">1,667</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,667</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.89</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Exercised, Forfeited or Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(135,168</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(135,168</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">9.42</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,358,678</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">373,333</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,732,011</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">10.67</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,906,571</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">373,333</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,279,904</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">12.22</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   The following table summarizes significant ranges of outstanding stock options under our plans at September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> Range of Exercise Prices</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total Number of Options</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Total Number of Options  Exercisable</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 22%">$1.75 - $5.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,271,809</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.83</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2.14</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">849,696</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.80</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2.19</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$5.01 – $11.00</td> <td> </td> <td> </td> <td style="text-align: right">178,335</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.19</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10.98</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">178,335</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.19</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10.98</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$11.01 – $15.00</td> <td> </td> <td> </td> <td style="text-align: right">766,292</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.44</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">13.91</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">736,715</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.41</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">13.88</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">$15.01 – $98.28</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">515,575</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">4.84</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">26.80</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">515,158</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">4.84</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">          26.81</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,732,011</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">7.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">10.67</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,279,904</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">6.77</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">12.22</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   There was no aggregate intrinsic value to the outstanding options and vested options as of September 30, 2018.   There were 734,864 and 3,980,781 warrants outstanding at September 30, 2018 and December 31, 2017, respectively at a weighted-average exercise price of $7.90 and $4.26, respectively.   Restricted Stock   In December 2017, the Company granted to its Chairman and Chief Executive Officer, 387,597 shares of restricted common stock, pursuant to the 2008 Plan. This restricted stock vests in equal annual instalments over three years. The fair value of the restricted stock is based on the market price of the Company’s shares on the grant date less the par value received as consideration. The fair value of the restricted stock on the grant date was $679,000. In December 2016, the Company granted to its Chairman and Chief Executive Officer, 387,597 shares of restricted common stock, pursuant to the 2008 Plan. This restricted stock vests in equal annual instalments over three years. The fair value of the restricted stock is based on the market price of the Company’s shares on the grant date less the par value received as consideration. The fair value of the restricted stock on the grant date was $1,000,000. The Company recorded an employee stock-based compensation expense for restricted stock of $140,827 and $417,889 respectively, for the three and nine-month periods ended September 30, 2018 as compared to $83,943 and $249,089 respectively, for the three and nine-month periods ended September 30, 2017.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%">Term Loan Principal</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 26%; text-align: right">9,986,362</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>End Fee Payable</td> <td> </td> <td> </td> <td style="text-align: right">1,771,250</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Issuance Cost/Loan Discount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,157,817</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Term Loan, Net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,599,795</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following reflects the weighted-average assumptions for each of the nine-month periods indicated:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 21%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 21%; text-align: right">1.31</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected lives</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.8</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">120.8</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Warrants classified as liabilities (in shares)</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,834,246</td> <td> </td></tr> </table> The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Consolidated Statements of Operations:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Three Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Research and development — employee</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">28,683</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">(124,405</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">89,105</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">507,211</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative — employee</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">243,673</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">479,330</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">799,832</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,348,815</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total employee stock-based compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">272,356</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">354,925</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">888,937</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,856,026</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Research and development — non-employee</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">11,600</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">11,600</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">General and administrative — non-employee</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">19,517</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">32,581</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">60,384</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">97,818</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total non-employee stock-based compensation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">19,517</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">44,181</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">60,384</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">109,418</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 25%; text-align: right">2.42</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 25%; text-align: right">2.32</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right">91.6</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">90.7</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected lives (years)</td> <td> </td> <td> </td> <td style="text-align: right">6</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">	6 to 10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td>%</td></tr> </table>

Presented below is our stock option activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">Nine Months Ended September 30, 2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options (Employees)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options (Non-Employees)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total Number of Options</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 32%">Outstanding at January 1, 2018</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">2,492,179</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">373,333</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">2,865,512</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 12%; text-align: right">10.62</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Granted</td> <td> </td> <td> </td> <td style="text-align: right">1,667</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,667</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.89</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Exercised, Forfeited or Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(135,168</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">—</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(135,168</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">9.42</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,358,678</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">373,333</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,732,011</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">10.67</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,906,571</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">373,333</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,279,904</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">12.22</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes significant ranges of outstanding stock options under our plans at September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> Range of Exercise Prices</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total Number of Options</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Total Number of Options  Exercisable</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Remaining Contractual Life (years)</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted-Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 22%">$1.75 - $5.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,271,809</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.83</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2.14</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">849,696</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">8.80</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2.19</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>$5.01 – $11.00</td> <td> </td> <td> </td> <td style="text-align: right">178,335</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.19</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10.98</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">178,335</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.19</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">10.98</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>$11.01 – $15.00</td> <td> </td> <td> </td> <td style="text-align: right">766,292</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.44</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">13.91</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">736,715</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6.41</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">13.88</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">$15.01 – $98.28</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">515,575</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">4.84</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">26.80</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">515,158</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right">4.84</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt">$</td> <td style="padding-bottom: 1.5pt; text-align: right">          26.81</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,732,011</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">7.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">10.67</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,279,904</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right">6.77</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">$</td> <td style="padding-bottom: 2.5pt; text-align: right">12.22</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes fair value measurements by level at September 30, 2018 for assets and liabilities measured at fair value on a recurring basis:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">(In thousands)</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level I</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level II</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level III</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Cash equivalents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">21,462</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">21,462</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The following table summarizes fair value measurements by level at December 31, 2017 for assets and liabilities measured at fair value on a recurring basis:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">(In thousands)</td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level I</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level II</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Level III</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Cash equivalents</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">35,834</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">35,834</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrant liabilities</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(527</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(527</td> <td>)</td></tr> </table>

21462000

35834000

21462000

35834000

527000 527000

285000000

310600000

285000000

236200000

2037-12-31

2018-12-31

7500000

1000000

5800000

5600000

6500000

9200000 6900000 600000 1700000

13000000

0.92

500000

105691

6.60

12.30

343000000

120000000

250000

4200000 3400000

7600

15000

1300

2000

0.060

100000

100000 2018-08-01 0.80 P30D 77000 200000 9986362 1771250 1157817

3500000

6500000

3500000

6500000

0.0242

0.0232

0.0131

0.0000

0.00

P6Y

P0Y

P9M18D

P6Y

P10Y

0.916

0.907

1.208

2010-08-06

2732011

2865512

2492179

2358678

373333

28897

2700000

800000

P10Y

700000

P9M25D

734864

3980781

7.90 4.26

387597

P3Y

679000

1000000

417889

249089

140827

83943

60384

89105

888937

60384

799832

109418

97818

507211

1348815

1856026

11600

28683

-124405

243673

479330

272356

354925

11600

19517

32581

19517

44181

1667

-135168 -135168

2279904

1906571

373333

10.67

10.62

1.89

3.96

9.42

12.22

5.01

15.01

1.75

11.01

11.00

98.28

5.00

15.00

2732011

515575

1271809

766292

178335

P7Y1M6D

P4Y2M8D

P4Y10M3D

P8Y9M29D

P6Y5M9D

10.67

26.80

2.14

13.91

10.98

2279904

515158

849696

736715

178335

P6Y9M7D

P4Y2M8D

P4Y10M3D

P8Y9M18D

P6Y4M28D

12.22

26.81

2.19

13.88

10.98

0.05 2018 false false false

5981040

7529032

1252186

1914077

31901565

47086513

646500

1042892

183780

34334

32766179

48347519

2900758

4122017

7515258

8029274

527025

10599795

10416016

30202464

33637

28037

476843206

468969445

-454526680

-450852427

22350163

18145055

32766179

48347519

250000

3186839

17675079

909712

4755191

6514107

9534872

2360996

3418808

-9450946

-27209951

-3020708

-8173999

269299

271292

93391

119900

1715733

2999230

363086

828120

-5848

-16722

-641

-6055

-10376203

-30526820

-3291044

-5124419

-0.34

-1.33

-0.10

-0.19

30242788

22936843

32991506

26618098

407870

492944

1367210

2214533

1157817

1363566

-424050

-1547992

256474

-661891

-1430644

-1221259

-1372697

-736419

-1124798

-7718126

-19858490

11478

134598

-11478

-134598

6512151

13951218

3202858

-5245461

9029245

-12975065

-10963843

24668339

37643404

56959485

45995642

647308

1749174

800

1894589

6924353

6075647

76549 138187 4000000 6000000

1771250

200000

CYTR

6924353

9700946

27209951

3270708

8173999

6.60

2019-01-26

6700000

300000

3200000

25000000

0.110

2018-08-01

633749

12.30

4.62

2834246

1667

35000

EX-101.SCH 7 cytr-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Description of Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Foreign Currency Remeasurement link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Recently Adopted Accounting Pronouncement link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Term Loan link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Basic and Diluted Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Warrant Liabilities link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Liquidity and Capital Resources link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Term Loan (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Warrant Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Description of Company and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Foreign Currency Remeasurement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Recently Adopted Accounting Pronouncement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Term Loan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Term Loan - Schedule of Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Warrant Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Warrant Liabilities - Schedule of Weighted-average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stock Based Compensation - Schedule of Total Stock-based Compensation Expense from Stock Options and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stock Based Compensation - Schedule of Share-based Payment Award, Fair Value of the Stock Options Granted, Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stock Based Compensation - Schedule of Outstanding Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements by Level for Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Liquidity and Capital Resources (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Equity Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cytr-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cytr-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cytr-20180930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Junior Participating Preferred Stock [Member] Legal Entity [Axis] Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] Variable Rate [Axis] Prime Rate [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Loan Agreement [Member] Derivative Instrument [Axis] Warrants [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Measurement Frequency [Axis] Recurring [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Long Lived Assets Held-for-sale by Asset Type [Axis] Other General and Administrative Expenses [Member] Contract Liabilities [Member] Tax Period [Axis] Latest Tax Year [Member] Earliest Tax Year [Member] Income Tax Authority [Axis] State [Member] Federal [Member] Award Type [Axis] Stock Options [Member] Exercise Price Range [Axis] Exercise Price Range Two [Member] Exercise Price Range Four [Member] Exercise Price Range One [Member] Exercise Price Range Three [Member] Title of Individual [Axis] Employees [Member] Non Employees [Member] Stock Options And Warrants [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Plan Name [Axis] 2000 Long Term Incentive Plan [Member] Restricted Stock [Member] 2008 Stock Incentive Plan [Member] Preferred Stock [Member] Centurion BioPharma Corporation [Member] NantCell, Inc [Member] Reimbursement Agreement [Member] Range [Axis] Maximum [Member] Equity Components [Axis] Current and Former Employees, Directors [Member] Chairman and Chief Executive Officer [Member] Orphazyme [Member] Related Party [Axis] EMA [Member] FDA [Member] Minimum [Member] Adjustments for New Accounting Pronouncements [Axis] ASU 2014-09 [Member] Retained Earnings [Member] Initial Application Period Cumulative Effect Transition [Axis] Difference Between Revenue Guidance In Effect Before and After Topic 606 [Member] Tax Year 2018 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets: Cash and cash equivalents Receivables Prepaid expenses and other current assets Total current assets Equipment and furnishings, net Goodwill Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Deferred revenue Warrant liabilities Term loan, net Total liabilities Commitments and contingencies Stockholders' equity: Preferred Stock, value Common stock, $0.001 par value, 41,666,667 shares authorized; 33,637,501 shares issued and outstanding at September 30, 2018; 28,037,501 shares issued and outstanding at December 31, 2017 Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, stated value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue: Licensing revenue Expenses: Research and development General and administrative Total expenses Loss before other income Other income (loss): Interest income Interest expense Other (loss), net Gain (loss) on warrant derivative liabilities Net loss Basic and diluted net loss per share Basic and diluted weighted-average shares outstanding Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation expense Fair value adjustment on warrant liabilities Amortization of loan cost and discount Loss on retirement of fixed assets Changes in assets and liabilities: Receivables Prepaid expenses and other current assets Accounts payable Deferred revenue Accrued expenses and other current liabilities Net cash used in operating activities Cash flows from investing activities: Purchases of equipment and furnishings Net cash used in investing activities Cash flows from financing activities: Proceeds from public offering Proceeds from sale of common shares and warrants related to NantCell Loan end fee payment Payment of principal on term loan Net proceeds from exercise of warrants and stock options Net cash provided by (used in) financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Cash paid during the year for interest Cash paid for income taxes Supplemental disclosure of non-cash activities: Warrant liability exercise Warrants repriced in connection with debt modification One for six reverse stock split Accounting Policies [Abstract] Description of Company and Basis of Presentation Foreign Currency [Abstract] Foreign Currency Remeasurement New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Recently Adopted Accounting Pronouncement Recent Accounting Pronouncements Debt Disclosure [Abstract] Term Loan Earnings Per Share [Abstract] Basic and Diluted Net Loss Per Common Share Warrant Liabilities [Abstract] Warrant Liabilities Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Based Compensation Fair Value Disclosures [Abstract] Fair Value Measurements Liquidity and Capital Resources [Abstract] Liquidity and Capital Resources Equity [Abstract] Equity Transactions Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Schedule of Term Loan EX-101.PRE 11 cytr-20180930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 02, 2018
Document And Entity Information
Entity Registrant Name	CYTRX CORP
Entity Central Index Key	0000799698
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business Flag	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		33,637,501
Trading Symbol	CYTR
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 24,668,339	$ 37,643,404
Receivables	5,981,040	7,529,032
Prepaid expenses and other current assets	1,252,186	1,914,077
Total current assets	31,901,565	47,086,513
Equipment and furnishings, net	646,500	1,042,892
Goodwill	183,780	183,780
Other assets	34,334	34,334
Total assets	32,766,179	48,347,519
Current liabilities:
Accounts payable	2,900,758	4,122,017
Accrued expenses and other current liabilities	7,515,258	8,029,274
Deferred revenue		6,924,353
Warrant liabilities		527,025
Term loan, net		10,599,795
Total liabilities	10,416,016	30,202,464
Commitments and contingencies
Stockholders' equity:
Preferred Stock, value
Common stock, $0.001 par value, 41,666,667 shares authorized; 33,637,501 shares issued and outstanding at September 30, 2018; 28,037,501 shares issued and outstanding at December 31, 2017	33,637	28,037
Additional paid-in capital	476,843,206	468,969,445
Accumulated deficit	(454,526,680)	(450,852,427)
Total stockholders' equity	22,350,163	18,145,055
Total liabilities and stockholders' equity	32,766,179	48,347,519
Series A Junior Participating Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, value
Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, value

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, stated value	$ 1,000	$ 1,000
Preferred stock, shares authorized	833,334	833,334
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	41,666,667	41,666,667
Common stock, shares issued	33,637,501	28,037,501
Common stock, shares outstanding	33,637,501	28,037,501
Series A Junior Participating Preferred Stock [Member]
Preferred stock, shares authorized	4,167	4,167
Preferred Stock [Member]
Preferred stock, shares authorized	650	650
Preferred stock, shares issued
Preferred stock, shares outstanding

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue:
Licensing revenue	$ 250,000		$ 250,000
Expenses:
Research and development	909,712	4,755,191	3,186,839	17,675,079
General and administrative	2,360,996	3,418,808	6,514,107	9,534,872
Total expenses	3,270,708	8,173,999	9,700,946	27,209,951
Loss before other income	(3,020,708)	(8,173,999)	(9,450,946)	(27,209,951)
Other income (loss):
Interest income	93,391	119,900	269,299	271,292
Interest expense	(363,086)	(828,120)	(1,715,733)	(2,999,230)
Other (loss), net	(641)	(6,055)	(5,848)	(16,722)
Gain (loss) on warrant derivative liabilities		3,763,855	527,025	(572,209)
Net loss	$ (3,291,044)	$ (5,124,419)	$ (10,376,203)	$ (30,526,820)
Basic and diluted net loss per share	$ (0.10)	$ (0.19)	$ (0.34)	$ (1.33)
Basic and diluted weighted-average shares outstanding	32,991,506	26,618,098	30,242,788	22,936,843

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (10,376,203)	$ (30,526,820)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	407,870	492,944
Stock-based compensation expense	1,367,210	2,214,533
Fair value adjustment on warrant liabilities	(527,025)	572,209
Amortization of loan cost and discount	1,157,817	1,363,566
Loss on retirement of fixed assets		424,050
Changes in assets and liabilities:
Receivables	1,547,992	(256,474)
Prepaid expenses and other current assets	661,891	1,430,644
Accounts payable	(1,221,259)	(1,372,697)
Deferred revenue		6,924,353
Accrued expenses and other current liabilities	(736,419)	(1,124,798)
Net cash used in operating activities	(7,718,126)	(19,858,490)
Cash flows from investing activities:
Purchases of equipment and furnishings	(11,478)	(134,598)
Net cash used in investing activities	(11,478)	(134,598)
Cash flows from financing activities:
Proceeds from public offering	6,512,151	13,951,218
Proceeds from sale of common shares and warrants related to NantCell		6,075,647
Loan end fee payment	(1,771,250)	(200,000)
Payment of principal on term loan	(9,986,362)	(14,000,478)
Net proceeds from exercise of warrants and stock options		3,202,858
Net cash provided by (used in) financing activities	(5,245,461)	9,029,245
Net decrease in cash and cash equivalents	(12,975,065)	(10,963,843)
Cash and cash equivalents at beginning of period	37,643,404	56,959,485
Cash and cash equivalents at end of period	24,668,339	45,995,642
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	647,308	1,749,174
Cash paid for income taxes	800	800
Supplemental disclosure of non-cash activities:
Warrant liability exercise		1,894,589
Warrants repriced in connection with debt modification		76,549
One for six reverse stock split		$ 138,187

XML 17 R6.htm IDEA: XBRL DOCUMENT

Description of Company and Basis of Presentation

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Description of Company and Basis of Presentation

1.	Description of Company and Basis of Presentation

There are two key elements to Centurion’s strategy:

	1.	A novel companion diagnostic, ACDx™ (albumin companion diagnostic), developed to identify patients with cancer who are most likely to benefit from treatment with Centurion’s lead assets.

	2.	Development of its four albumin binding, linker activated drug release (LADR) oncology candidates.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Foreign Currency Remeasurement

9 Months Ended

Sep. 30, 2018

Foreign Currency [Abstract]

Foreign Currency Remeasurement

2.	Foreign Currency Remeasurement

XML 19 R8.htm IDEA: XBRL DOCUMENT

Recently Adopted Accounting Pronouncement

9 Months Ended

Sep. 30, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recently Adopted Accounting Pronouncement

3.	Recently Adopted Accounting Pronouncement

XML 20 R9.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recent Accounting Pronouncements

4.	Recent Accounting Pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

Term Loan

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Term Loan

5.	Term Loan

	December 31, 2017
Term Loan Principal	$	9,986,362
End Fee Payable		1,771,250
Issuance Cost/Loan Discount		(1,157,817	)
Term Loan, Net	$	10,599,795

XML 22 R11.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Basic and Diluted Net Loss Per Common Share

6.	Basic and Diluted Net Loss Per Common Share

XML 23 R12.htm IDEA: XBRL DOCUMENT

Warrant Liabilities

9 Months Ended

Sep. 30, 2018

Warrant Liabilities [Abstract]

Warrant Liabilities

7.	Warrant Liabilities

	September 30, 2018		December 31, 2017
Risk-free interest rate		—		1.31	%
Expected dividend yield		—		0	%
Expected lives		—		0.8
Expected volatility		—		120.8	%
Warrants classified as liabilities (in shares)		—		2,834,246

On July 20, 2018, 2,834,246 warrants classified as liabilities expired.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock Based Compensation

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Based Compensation

8.	Stock Based Compensation

We follow ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.

For stock options and stock warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50.

The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Consolidated Statements of Operations:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2018		2017			2018		2017
Research and development — employee	$	28,683	$	(124,405	)	$	89,105	$	507,211
General and administrative — employee		243,673		479,330			799,832		1,348,815
Total employee stock-based compensation	$	272,356	$	354,925		$	888,937	$	1,856,026

Research and development — non-employee	$	—	$	11,600		$	—	$	11,600
General and administrative — non-employee		19,517		32,581			60,384		97,818
Total non-employee stock-based compensation	$	19,517	$	44,181		$	60,384	$	109,418

	Nine Months Ended September 30, 2018			Nine Months Ended September 30, 2017
Risk-free interest rate		2.42	%		2.32	%
Expected volatility		91.6	%		90.7	%
Expected lives (years)		6			6 to 10
Expected dividend yield		0.00	%		0.00	%

	Nine Months Ended September 30, 2018
	Number of Options (Employees)			Number of Options (Non-Employees)		Total Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2018		2,492,179			373,333		2,865,512		$	10.62
Granted		1,667			—		1,667		$	1.89
Exercised, Forfeited or Expired		(135,168	)		—		(135,168	)	$	9.42
Outstanding at September 30, 2018		2,358,678			373,333		2,732,011		$	10.67
Options exercisable at September 30, 2018		1,906,571			373,333		2,279,904		$	12.22

The following table summarizes significant ranges of outstanding stock options under our plans at September 30, 2018:

Range of Exercise Prices	Total Number of Options		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price		Total Number of Options Exercisable		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price
$1.75 - $5.00		1,271,809		8.83	$	2.14		849,696		8.80	$	2.19
$5.01 – $11.00		178,335		4.19	$	10.98		178,335		4.19	$	10.98
$11.01 – $15.00		766,292		6.44	$	13.91		736,715		6.41	$	13.88
$15.01 – $98.28		515,575		4.84	$	26.80		515,158		4.84	$	26.81
		2,732,011		7.10	$	10.67		2,279,904		6.77	$	12.22

There was no aggregate intrinsic value to the outstanding options and vested options as of September 30, 2018.

There were 734,864 and 3,980,781 warrants outstanding at September 30, 2018 and December 31, 2017, respectively at a weighted-average exercise price of $7.90 and $4.26, respectively.

Restricted Stock

XML 25 R14.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

9.	Fair Value Measurements

Level 1 – quoted prices in active markets for identical assets or liabilities.

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at September 30, 2018 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III		Total
Cash equivalents	$	21,462	$	—	$	—	$	21,462

The following table summarizes fair value measurements by level at December 31, 2017 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	35,834	$	—	$	—		$	35,834
Warrant liabilities		—		—		(527	)		(527	)

We consider carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Liquidity and Capital Resources

9 Months Ended

Sep. 30, 2018

Liquidity and Capital Resources [Abstract]

Liquidity and Capital Resources

10.	Liquidity and Capital Resources

XML 27 R16.htm IDEA: XBRL DOCUMENT

Equity Transactions

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Equity Transactions

11.

Equity Transactions

On May 15, 2018, we issued 5.6 million shares of our common stock in a public offering and raised net proceeds of approximately $6.5 million.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

12.

Income Taxes

XML 29 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

13.

Commitments and contingencies

Commitments

		●	commercially reasonable royalties based on a percentage of net sales (as defined in the agreement);

		●	a percentage of non-royalty sub-licensing income (as defined in the agreement); and

		●	milestones of $1 million for each additional final marketing approval that we obtain.

Contingencies

XML 30 R19.htm IDEA: XBRL DOCUMENT

Term Loan (Tables)

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Schedule of Term Loan

	December 31, 2017
Term Loan Principal	$	9,986,362
End Fee Payable		1,771,250
Issuance Cost/Loan Discount		(1,157,817	)
Term Loan, Net	$	10,599,795

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

Warrant Liabilities (Tables)

9 Months Ended

Sep. 30, 2018

Warrant Liabilities [Abstract]

Schedule of Weighted-average Assumptions

The following reflects the weighted-average assumptions for each of the nine-month periods indicated:

	September 30, 2018		December 31, 2017
Risk-free interest rate		—		1.31	%
Expected dividend yield		—		0	%
Expected lives		—		0.8
Expected volatility		—		120.8	%
Warrants classified as liabilities (in shares)		—		2,834,246

XML 32 R21.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Total Stock-based Compensation Expense from Stock Options and Warrants

The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in our Condensed Consolidated Statements of Operations:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2018		2017			2018		2017
Research and development — employee	$	28,683	$	(124,405	)	$	89,105	$	507,211
General and administrative — employee		243,673		479,330			799,832		1,348,815
Total employee stock-based compensation	$	272,356	$	354,925		$	888,937	$	1,856,026

Research and development — non-employee	$	—	$	11,600		$	—	$	11,600
General and administrative — non-employee		19,517		32,581			60,384		97,818
Total non-employee stock-based compensation	$	19,517	$	44,181		$	60,384	$	109,418

Schedule of Share-based Payment Award, Fair Value of the Stock Options Granted, Assumptions

The fair value of the stock options was estimated using the Black-Scholes option-pricing model, based on the following assumptions:

	Nine Months Ended September 30, 2018			Nine Months Ended September 30, 2017
Risk-free interest rate		2.42	%		2.32	%
Expected volatility		91.6	%		90.7	%
Expected lives (years)		6			6 to 10
Expected dividend yield		0.00	%		0.00	%

Schedule of Share-based Compensation, Stock Options, Activity

Presented below is our stock option activity:

	Nine Months Ended September 30, 2018
	Number of Options (Employees)			Number of Options (Non-Employees)		Total Number of Options			Weighted-Average Exercise Price
Outstanding at January 1, 2018		2,492,179			373,333		2,865,512		$	10.62
Granted		1,667			—		1,667		$	1.89
Exercised, Forfeited or Expired		(135,168	)		—		(135,168	)	$	9.42
Outstanding at September 30, 2018		2,358,678			373,333		2,732,011		$	10.67
Options exercisable at September 30, 2018		1,906,571			373,333		2,279,904		$	12.22

Schedule of Outstanding Stock Options

The following table summarizes significant ranges of outstanding stock options under our plans at September 30, 2018:

Range of Exercise Prices	Total Number of Options		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price		Total Number of Options Exercisable		Weighted-Average Remaining Contractual Life (years)		Weighted-Average Exercise Price
$1.75 - $5.00		1,271,809		8.83	$	2.14		849,696		8.80	$	2.19
$5.01 – $11.00		178,335		4.19	$	10.98		178,335		4.19	$	10.98
$11.01 – $15.00		766,292		6.44	$	13.91		736,715		6.41	$	13.88
$15.01 – $98.28		515,575		4.84	$	26.80		515,158		4.84	$	26.81
		2,732,011		7.10	$	10.67		2,279,904		6.77	$	12.22

XML 33 R22.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of Fair Value Measurements by Level for Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes fair value measurements by level at September 30, 2018 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III		Total
Cash equivalents	$	21,462	$	—	$	—	$	21,462

The following table summarizes fair value measurements by level at December 31, 2017 for assets and liabilities measured at fair value on a recurring basis:

(In thousands)	Level I		Level II		Level III			Total
Cash equivalents	$	35,834	$	—	$	—		$	35,834
Warrant liabilities		—		—		(527	)		(527	)

XML 34 R23.htm IDEA: XBRL DOCUMENT

Description of Company and Basis of Presentation (Details Narrative) - USD ($)			1 Months Ended	9 Months Ended	12 Months Ended
	Oct. 03, 2017	Jul. 27, 2017	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2011	Jun. 01, 2018
Percentage of service charge						5.00%
Cash investment		$ 13,000,000
Investment in common stock per share		$ 6.60
Common stock market price premium percentage		92.00%
Number of warrants issued to purchase shares of common stock		500,000
Warrants exercise price per share		$ 6.60
Warrant expiration		Jan. 26, 2019
Milestone payments receivable		$ 343,000,000	$ 250,000
EMA [Member]
Payments for milestone				$ 4,000,000
FDA [Member]
Payments for milestone				$ 6,000,000
NantCell, Inc [Member] \| Reimbursement Agreement [Member] \| Maximum [Member]
Payments for reimbursement	$ 4,200,000
Anticipated reimbursement	$ 3,400,000
Orphazyme [Member]
Milestone payments receivable					$ 120,000,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

Foreign Currency Remeasurement (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Foreign Currency [Abstract]
Loss on foreign currency translation adjustment	$ 1,300	$ 2,000	$ 7,600	$ 15,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Recently Adopted Accounting Pronouncement (Details Narrative) - ASU 2014-09 [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Jan. 02, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract with customer, liability, revenue recognized	$ 3,200,000
Difference Between Revenue Guidance In Effect Before and After Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability		$ 300,000
Retained Earnings [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cumulative effect adjustment		$ 6,700,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Term Loan (Details Narrative) - USD ($)				2 Months Ended	3 Months Ended		9 Months Ended
Term Loan (Details Narrative) - USD ($)	Jul. 28, 2017	Jul. 28, 2017	Feb. 08, 2016	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jul. 27, 2017
Number of warrants issued									500,000
Warrants exercise price									$ 6.60
Debt instrument, repayment of principal and unpaid interest							$ 9,986,362	$ 14,000,478
Interest expense					$ 363,086	$ 828,120	$ 1,715,733	$ 2,999,230
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member]
Aggregate principal amount			$ 25,000,000
Debt instrument, interest rate			11.00%
Debt instrument, description			The Term Loans bear interest at the daily variable rate per annum equal to 6.0% plus the prime rate, or 11.0%, whichever is greater. CytRx was required to make interest-only payments on the Term Loans through February 28, 2017, and beginning on March 1, 2017 blended equal monthly installments of principal amortization and accrued interest until the maturity date of the Term Loans on February 1, 2020.
Debt instrument, maturity date			Aug. 01, 2018
Number of days to calculate volume-weighted average price of common stock							30 days
Warrants repriced in connection with the sale of licenses							$ 77,000
Additional loan discount					$ 200,000		$ 200,000
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Loan Agreement [Member]
Debt instrument, repayment of principal and unpaid interest	$ 5,000,000			$ 5,000,000
Prepayment charge	$ 100,000
Second prepayment charge				$ 100,000
Maturity date of amended loan servicing agreement	Aug. 01, 2018
Percentage of stock issuable upon exercise of the warrants	80.00%
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Warrants [Member]
Number of warrants issued			105,691
Warrants exercise price			$ 12.30
Fair value of warrants classified as equity warrants			$ 633,749
Warrant, exercise price, increase		$ 12.30
Warrant, exercise price, decrease		$ 4.62
Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. [Member] \| Prime Rate [Member]
Debt instrument, basis spread on variable rate			6.00%

XML 38 R27.htm IDEA: XBRL DOCUMENT

Term Loan - Schedule of Term Loan (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Term Loan Principal		$ 9,986,362
End Fee Payable		1,771,250
Issuance Cost/Loan Discount		(1,157,817)
Term Loan, Net		$ 10,599,795

XML 39 R28.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	3,500,000	6,500,000	3,500,000	6,500,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Warrant Liabilities (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
Warrant Liabilities (Details Narrative) - USD ($)	Jul. 20, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Gain (loss) on warrant derivative liabilities			$ 3,763,855	$ 527,025	$ (572,209)
Warrants expired	2,834,246
Warrants [Member]
Gain (loss) on warrant derivative liabilities		$ 0	$ 3,800,000	$ 500,000	$ (600,000)

XML 41 R30.htm IDEA: XBRL DOCUMENT

Warrant Liabilities - Schedule of Weighted-average Assumptions (Details) - shares		9 Months Ended		12 Months Ended
	Jul. 20, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Risk-free interest rate		2.42%	2.32%
Expected dividend yield		0.00%	0.00%
Expected lives		6 years
Expected volatility		91.60%	90.70%
Warrants classified as liabilities (in shares)	2,834,246
Warrants [Member]
Risk-free interest rate				1.31%
Expected dividend yield				0.00%
Expected lives		0 years		9 months 18 days
Expected volatility				120.80%
Warrants classified as liabilities (in shares)				2,834,246

XML 42 R31.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
Stock Based Compensation (Details Narrative) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Share-based compensation, shares subject to stock options	2,865,512		2,732,011		2,732,011		2,865,512
Weighted average exercise price of stock options granted					$ 1.89
Expected dividend yield					0.00%	0.00%
Warrants [Member]
Expected dividend yield							0.00%
Warrants outstanding	3,980,781		734,864		734,864		3,980,781
Weighted-average exercise price of warrants outstanding	$ 4.26		$ 7.90		$ 7.90		$ 4.26
Current and Former Employees, Directors [Member]
Unrecognized compensation expense related to unvested stock options, granted			$ 700,000		$ 700,000
Unrecognized compensation cost, recognized as expense over a weighted-average period					9 months 25 days
Restricted Stock [Member]
Restricted stock expense			$ 140,827	$ 83,943	$ 417,889	$ 249,089
Stock Options [Member]
Number of stock options granted to purchase common stock					1,667	35,000
Weighted average exercise price of stock options granted					$ 1.89	$ 3.96
Contractual term					10 years
Expected dividend yield					0.00%
2000 Long Term Incentive Plan [Member]
Expiration date					Aug. 06, 2010
Share-based compensation, shares subject to stock options			28,897		28,897
2008 Stock Incentive Plan [Member]
Share-based compensation, shares subject to stock options			2,700,000		2,700,000
2008 Stock Incentive Plan [Member] \| Restricted Stock [Member]
Share-based compensation, outstanding stock options			800,000		800,000
2008 Stock Incentive Plan [Member] \| Restricted Stock [Member] \| Chairman and Chief Executive Officer [Member]
Share based compensation arranged by share based payment award restricted stock granted	387,597	387,597
Vesting period	3 years	3 years
Share based compensation of fair value of restricted stock on grant	$ 679,000	$ 1,000,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Stock Based Compensation - Schedule of Total Stock-based Compensation Expense from Stock Options and Warrants (Details) - Stock Options And Warrants [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Employees [Member]
Allocated employee and non-employee stock-based compensation expense, Total	$ 272,356	$ 354,925	$ 888,937	$ 1,856,026
Non Employees [Member]
Allocated employee and non-employee stock-based compensation expense, Total	19,517	44,181	60,384	109,418
Research and Development Expense [Member] \| Employees [Member]
Allocated employee and non-employee stock-based compensation expense, Total	28,683	(124,405)	89,105	507,211
Research and Development Expense [Member] \| Non Employees [Member]
Allocated employee and non-employee stock-based compensation expense, Total		11,600		11,600
General and Administrative Expense [Member] \| Employees [Member]
Allocated employee and non-employee stock-based compensation expense, Total	243,673	479,330	799,832	1,348,815
General and Administrative Expense [Member] \| Non Employees [Member]
Allocated employee and non-employee stock-based compensation expense, Total	$ 19,517	$ 32,581	$ 60,384	$ 97,818

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stock Based Compensation - Schedule of Share-based Payment Award, Fair Value of the Stock Options Granted, Assumptions (Details)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Risk-free interest rate	2.42%	2.32%
Expected volatility	91.60%	90.70%
Expected lives (years)	6 years
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Expected lives (years)		6 years
Maximum [Member]
Expected lives (years)		10 years

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stock Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Number of Options Outstanding at beginning of period	2,865,512
Number of Options Granted	1,667
Number of Options Exercised, Forfeited or Expired	(135,168)
Number of Options Outstanding at end of period	2,732,011
Number of Options exercisable at end of period	2,279,904
Weighted-Average Exercise Price Options Outstanding at beginning of period	$ 10.62
Weighted-Average Exercise Price Options Granted	1.89
Weighted-Average Exercise Price Options Exercised, Forfeited or Expired	9.42
Weighted-Average Exercise Price Options Outstanding at end of period	10.67
Weighted-Average Exercise Price Options exercisable at end of period	12.22
Stock Options [Member]
Weighted-Average Exercise Price Options Granted	$ 1.89	$ 3.96
Stock Options [Member] \| Employees [Member]
Number of Options Outstanding at beginning of period	2,492,179
Number of Options Granted	1,667
Number of Options Exercised, Forfeited or Expired	(135,168)
Number of Options Outstanding at end of period	2,358,678
Number of Options exercisable at end of period	1,906,571
Stock Options [Member] \| Non Employees [Member]
Number of Options Outstanding at beginning of period	373,333
Number of Options Granted
Number of Options Exercised, Forfeited or Expired
Number of Options Outstanding at end of period	373,333
Number of Options exercisable at end of period	373,333

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stock Based Compensation - Schedule of Outstanding Stock Options (Details)	9 Months Ended
	Sep. 30, 2018 $ / shares shares
Number of Options Outstanding \| shares	2,732,011
Weighted-Average Remaining Contractual Life (years)	7 years 1 month 6 days
Weighted-Average Exercise Price	$ 10.67
Number of Options Exercisable \| shares	2,279,904
Weighted-Average Remaining Contractual Life (years)	6 years 9 months 7 days
Weighted-Average Exercise Price, Options Exercisable	$ 12.22
Stock Options [Member] \| Exercise Price Range One [Member]
Range of Exercise Prices, Lower Range	1.75
Range of Exercise Prices, Upper Range	$ 5.00
Number of Options Outstanding \| shares	1,271,809
Weighted-Average Remaining Contractual Life (years)	8 years 9 months 29 days
Weighted-Average Exercise Price	$ 2.14
Number of Options Exercisable \| shares	849,696
Weighted-Average Remaining Contractual Life (years)	8 years 9 months 18 days
Weighted-Average Exercise Price, Options Exercisable	$ 2.19
Stock Options [Member] \| Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Range	5.01
Range of Exercise Prices, Upper Range	$ 11.00
Number of Options Outstanding \| shares	178,335
Weighted-Average Remaining Contractual Life (years)	4 years 2 months 8 days
Weighted-Average Exercise Price	$ 10.98
Number of Options Exercisable \| shares	178,335
Weighted-Average Remaining Contractual Life (years)	4 years 2 months 8 days
Weighted-Average Exercise Price, Options Exercisable	$ 10.98
Stock Options [Member] \| Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Range	11.01
Range of Exercise Prices, Upper Range	$ 15.00
Number of Options Outstanding \| shares	766,292
Weighted-Average Remaining Contractual Life (years)	6 years 5 months 9 days
Weighted-Average Exercise Price	$ 13.91
Number of Options Exercisable \| shares	736,715
Weighted-Average Remaining Contractual Life (years)	6 years 4 months 28 days
Weighted-Average Exercise Price, Options Exercisable	$ 13.88
Stock Options [Member] \| Exercise Price Range Four [Member]
Range of Exercise Prices, Lower Range	15.01
Range of Exercise Prices, Upper Range	$ 98.28
Number of Options Outstanding \| shares	515,575
Weighted-Average Remaining Contractual Life (years)	4 years 10 months 3 days
Weighted-Average Exercise Price	$ 26.80
Number of Options Exercisable \| shares	515,158
Weighted-Average Remaining Contractual Life (years)	4 years 10 months 3 days
Weighted-Average Exercise Price, Options Exercisable	$ 26.81

XML 47 R36.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Fair Value Measurements (Details Narrative) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Decrease in fair value of the warrant liabilities		$ 3,763,855	$ 527,025	$ (572,209)

XML 48 R37.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value Measurements by Level for Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Cash equivalents	$ 21,462	$ 35,834
Warrant liabilities		(527)
Fair Value, Inputs, Level 1 [Member] \| Recurring [Member]
Cash equivalents	21,462	35,834
Warrant liabilities
Fair Value, Inputs, Level 2 [Member] \| Recurring [Member]
Cash equivalents
Warrant liabilities
Fair Value, Inputs, Level 3 [Member] \| Recurring [Member]
Cash equivalents
Warrant liabilities		$ (527)

XML 49 R38.htm IDEA: XBRL DOCUMENT

Liquidity and Capital Resources (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 24,668,339	$ 37,643,404	$ 45,995,642	$ 56,959,485
Projected expenditures for preclinical programs	9,200,000
Centurion BioPharma Corporation [Member]
Projected expenditures for preclinical programs	1,700,000
Contract Liabilities [Member]
Projected expenditures for preclinical programs	600,000
Other General and Administrative Expenses [Member]
Projected expenditures for preclinical programs	$ 6,900,000

XML 50 R39.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details Narrative)	May 15, 2018 USD ($) shares
Equity [Abstract]
Common stock shares issued \| shares	5,600,000
Value of common stock shares issued \| $	$ 6,500,000

XML 51 R40.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative)	12 Months Ended
Income Taxes (Details Narrative)	Dec. 31, 2017 USD ($)
Latest Tax Year [Member]
Expiration date	Dec. 31, 2037
Earliest Tax Year [Member]
Expiration date	Dec. 31, 2018
Federal [Member]
Operating loss carryforwards	$ 310,600,000
Federal [Member] \| Tax Year 2018 [Member]
Operating loss carryforwards	236,200,000
State [Member]
Operating loss carryforwards	285,000,000
State [Member] \| Latest Tax Year [Member]
Operating loss carryforwards	$ 285,000,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)	9 Months Ended
Commitments and Contingencies (Details Narrative)	Sep. 30, 2018 USD ($) Integer
Commitments and Contingencies Disclosure [Abstract]
Amount of milestone payment payable	$ 7,500,000
Potential future milestone payments on each additional final marketing approval	$ 1,000,000
Number of competing derivative complaints \| Integer	2
Litigation settlements	$ 5,800,000

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ID8DT?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ "F1B32?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " *9&)-4Z\ F^T K @ $0 &1O8U!R;W!S+V-O M&ULS9+!2L0P$(9?17)OIVE%)'1S43PI""XHWD(RNQMLFI",M/OVIG&W MB^@#>,S,GV^^@>EU$-I'?(X^8"2+Z6IVPYB$#AMV( H"(.D#.I7JG!AS<^>C M4Y2?<0]!Z0^U1VB;Y@8AAPM@@1%&E[X+:%9BJ?Z)+1U@I^2<[)J:IJF>NI++.W!X M>WI\*>M6=DRD1HWY5[*"C@$W[#SYM;N[WSXPV3;\MN*\:MHM;T7'17?]OKC^ M\+L(.V_LSOYCX[.@[.'77<@O4$L#!!0 ( ID8DV97)PC$ 8 )PG 3 M >&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S M:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N M+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X M%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53" MQ,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@ MX_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMH MG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2 M%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9R MG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S M>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,B MUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C? MC8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1 MVC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE M"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ MZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J= MW#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B M(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)5 M8#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6Q MP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>; MG*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4< M!A87,N10[I*0!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E M$A2*L P%(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TSU#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+? M.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4 MJUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5 MBZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%0 M2P,$% @ "F1B3: 3MYB( @ 1@D !@ !X;"]W;W)K3. DZP-1VPO7M M:QN.H_;2/\$V,SN[S@YVV3/^*FZ42N^MJ5NQ]F]2=JL@$*<;;8AX8AUMU9L+ MXPV1:LJO@>@X)6=#:NH AV$:-*1J_4UIU@Y\4[*[K*N6'K@G[DU#^)\=K5F_ M]I'_OO!<76]2+P2;LB-7^H/*G]V!JUDP13E7#6U%Q5J/T\O:WZ+5'F6:8! O M%>W%;.SI4HZ,O>K)U_/:#W5&M*8GJ4,0]7C0/:UK'4GE\7L,ZD^:FC@?OT?_ M;(I7Q1R)H'M6_ZK.\K;V<]\[TPNYU_*9]5_H6%#B>V/UW^B#U@JN,U$:)U8+ M\^N=[D*R9HRB4FG(V_"L6O/LAS.LR(V T(/$.@"1&H MV), A@1VV*'C?P7V+B*"!2*P@LC0HQD]ANDQ2(\-/9[1$VL#7$0*"R2@0.+0 M,TM@0"0&T0Z(HDB+'%9)09744,B-X+]ET.8A>U"H'NW M"+L1"EL%P"RIP!9&D1,!.Y\A%[.H CL=N4;&R/H6C9BY%Z,HC;(D7.AD!)L> MN:['=B]#F*6*8-,CU]/8;N<1D\XQ2_T,.Q^YOL9./V?.ON$0V5^P8'8J-91? MS0$NO!.[M^;V,%N=+@E;;$ZU#_APP_A.^+5JA7=D4IV-Y@2[,":I2B9\4FG< MU*5FFM3T(O4P4V,^G.S#1+)NO+4$T]5I\Q=02P,$% @ "F1B3>1&N /F M P UA$ !@ !X;"]W;W)K6P7V;[K3@]YWF[VOBK:#_7)'\,_N[JIBBX4F^>\/36^ MV Y!59D#8SJOBL,Q6\Z'NL=F.:]?NO)P](_-K'VIJJ+Y;^7+^KS(>/96\>7P MO._ZBGPY/Q7/_E_??3T]-J&47UK9'BI_; _U<=;XW2+[R!_68@@8%-\._MQ> MW<_Z5)[J^D=?^&N[R%COR)=^T_5-%.'RZM>^+/N6@H^?4Z/9I<\^\/K^K?7/ M0_(AF:>B]>NZ_'[8=OM%9K/9UN^*E[+[4I__]%-"*IM-V?_M7WT9Y+V3T,>F M+MOA=[9Y:;NZFEH)5JKBUW@]'(?K>6K_+8P.@"D +@%Q&_X+V;:A]G4)9IZ_]NU,DM4H@6O) MK6)-*.Q%DH?^+R: - %#O+B.=W2$./%$"^OX@6+DA@E9I 0 C">V*:?)RC%:8T"M)LTMH;@"[ D++0,')C7_ M-%LYAJN,X4IIT*F%R:H=2*$2W. T6CEFJXQ91FF0'0Q6!8:!2KBAP6$$U7CO$J8Z!1 M&C1*=S6W3FBRP(1-;%&@< L:AC';>BM+$N=S7W#JA$0@/%14FV==E(F]@304 4,514### K M_Y!**@@/K?$)3VN952 A-6(T6@%C4\7/B8"Q"2!4V*PB]H65W/+@3*7&BR8L M8'JJF+" Z9DX\ GE_0,?:-("IJA*4 AH-H)Y_]ZG.08$?]#>?P?'[FMNG= < M _R(F)IE07-,L'>/AJ#Y(PC^Q*-!:>+1N*\9G>17+]C]%X]_BN;Y<&QG3W47 MWM6'-^I=77<^M,<^A+6V]\7V4BC]KNMO3;AOQB\-8Z&K3]-7E/SR*6?Y/U!+ M P04 " *9&)-'RC#5* " "L"@ & 'AL+W=O??NU MA4OH@Z(OI"W_<_H[4/XYJQNA;ZS$F'OO3=VRM5]RWBV#@!U*W"#V0CK ]91C(XJJ*F#$( T:%#5^IN56MO1S8I<>%VU>$<]=FD:1/\5N":W MM0_]CX77ZEQRN1!L5ATZXY^8_^IV5,R",XW,)4!BC% M[PK?V&3LR5+VA+S)R;?CV@>2"-?XP&4*)"Y7O,5U+3,)CK]#4G_<4P9.QQ_9 MOZCB13%[Q/"6U'^J(R_7?NY[1WQ"EYJ_DMM7/!24^-Y0_7=\Q;602Q*QQX'4 M3/U[APOCI!FR")0&O??7JE776W\G2X"KB,Q,,\R$7U[-0]42T3J]=-DJZ"J\PS2(I>$DXDH:[8 M.A3Y* G$_B-$Z(0(57P\A<@,B%Z2*TFK). %0(-C1J211$Z2R";)#9)>DDTV M@0 @V1&I)'$3I+8)ED8)+TDF6R21^(7&RRS,HTF<=(D%DUJE%S8DM@$P\E M&D7JI$AM"N,(%+;$HG@HT2@R)T5F4QA;%+UDH1]$Z[C.J326W,F2VRR1P9); MKS^&J?P9G]CV":%&M' 2+6PBXT 6"VNC*$JC++$>D"T,&=R)X/; M\N 3G@=M-TL3TWUG1#J+V_#@$X[GT%AF\UBCD[A-#S[A>@Z-3?*$[P63MD'V M<3\0/5,XJ?&)RV$FQK3OG_H))]W0&P9C M@[KY#U!+ P04 " *9&)-?8E-6-P# #0#P & 'AL+W=OD# M*UFN),?;;U_JB%?FC-S-0RQ1_YGA;WC.]%J4WZJ#<_7D>YZ=JEETJ.OS2QQ7 MFX/+T^JY.+N3_[(KRCRM_6NYCZMSZ=)M:Y1G,6(KFT[;MK9Q/BTN= M'4_NK9Q4ESQ/RW\7+BNNLPBBSX8OQ_VA;AKB^?2<[MU75_]Y?BO]6WSSLCWF M[E0=B].D=+M9] HO:]"-0:OXZ^BNU>!YTJ"\%\6WYN6W[2QB38]3[\4_O-+K%; R'SY_>?VGA/2$63GOYW]^$R+V]ZXF-LBJQJ_T\VEZHN\MZ+[TJ>?N]^CZ?V]]I] MT9]FM 'O#?C-P,=^9"!Z _'#0#XTD+V!_-D(JC=0082X8V^3N4KK=#XMB^ND M[.;#.6VF';PH/UR;IK$=G?:;SV?E6S_F23*-/QH_O6312?A0HN\E*RR!FR+V M\6^=X%0G%AR9\_L 2ZQ(3-"'_W6R?NCDKIN"S)5H[<70WM+VDK27K;T$4P3*IE0(+06*P3H!)C+!!9K .=*(5TR-CKDD^C?E$P*=1("X29FVP M#I=8)R08P\*%@'6) @DL6+1KK+-*2*-'QM^0? ;SR8#/X'YSS738[R76&=#" MVF!@5EAG-6-6!OE:8QW7W.=5C4Q02P):#*@"0(L"/0G&"4)"2",20BL5P4@( M'T,"HX\!AM=Q,N)AY" !G*A@QBUZS=W0"1&NT"4A [ VW+M6A(XGEH?97%,Z MOW_8D8D.Y"'U"AP#FA"0$U,A$%WV MFKM=32?"8#HL5'[[XRK$P[HGY>G8R'$#]'D,"O-!R*?0W>!)< M,RI"24"K@ M4D*X8U%*8#XEG*&)2H5GBB>&C\U4^NX ^/)@PLM#KS'#8.P9S51:A2!)F9 A M("&#Y\&"O8>C+PZ ;PXFO#D <27P2QX40_L-<5#-!^P)>ED"TKYIRM:U^ M?KCO:MT_TG)_/%63]Z+V-51;Z>R*HG8>@#W[KA]\>7U[R=RN;AZU?RZ[&K-[ MJ8MS7S_'MR)^_A]02P,$% @ "F1B38AA7.BS! ;A4 !@ !X;"]W M;W)KI.89#_.>U:>NRCY?MV[P[MJ'E[+PN]X?I M>VZ7B^:]K_:'\-Q.NO>Z+MM_5Z%J3H]3F'Z[\7G_MNN'&_/EXEB^A3]" M_^?QN8U7\VLKVWT=#MV^.4S:\/HX?8*'-;DA8%3\M0^G[N9\,J3RTC1?AHM? MMX]3-3@*5=CT0Q-E/'R$=:BJH:7HXY]+H]-KGT/@[?FWUG\>DX_)O)1=6#?5 MW_MMOWN<%M/)-KR6[U7_N3G]$BX)F>GDDOUOX2-443XXB7ULFJH;?R>;]ZYO MZDLKT4I=?CT?]X?Q>#K_X^PE3 [ 2P!> V+?/PJ@2P!]#]!C\F=G8ZH_E7VY M7+3-:=*>G]:Q'"8%/% 0>2,R!QGBZS<'(\5J,UV.\OHV'9 S.$C=*#J-D M!HJ<145),H*2E$%;H)(]&=&3X3E9.=Z*\9;GY)*H MO&S'BW8\L^.3M%>>#P\85T#R4->"CBP9FYD\H&0J*.XH+0E!H]/*OFCN)@]J M93*E !E& 2L&CYD61 8] 3*OQ/)!/G1&.^]94EPX0V.URY0$R-0"XIXP]42L M*VNA2)_%6M"!)F5S50HR"(&3D-*ZN&CNLH=8@FA\:DI2DD/K7<:5C$(P?**Q MAR=HV',S?# ]:C(9=(!,5N!HU6FU H?FS)'5P,9($ )@G':9-R#(@ 5.6$^I M*8[.F7-0 -K4E: $7YA"^USERIR%@E=N;DK*: 2!C29-C$,O#J)V19J6I"-M M"1I6^2A@5+D!V1D[,AZ1XQ%46OHH42^6&9IT)2,IX_>7 M4ID:0QF/R-$'*N4C>]]R9Q$SDE0Z0M.$/&GQQE) MJ##B*.-'1B1R1$*Z>E^A0#Z#VFC+YCA7>H7Q?9+Y]$"9D,B7HJ#2+S 4%J. MWAEET^6H*%7>4J$SKSF4P8L.R7)LB\]U',B-)8"2DC!1$W ]GI+-&Y]S(A"2!D) 24A!Q-XYM@@ 5 M4*0%,;_9I:I#^S9NZ'633?-^Z(<-H9N[UTW#)QQVN9+[*WA8G[?^OC=SWHG\ MO6S?]H=N\M+T?5./.UVO3=.':%-]BL.U"^7V>E&%UWXX=?&\/>\ GB_ZYGC9 MW9Q?MUB7_P%02P,$% @ "F1B39N[LKJT 0 T@, !@ !X;"]W;W)K MLM\#J"E&3I;G?#%!>:EGGTG6R9F\%+H>%DB1N4XO;M M"-*,!4WHN^-9M)T/#E;F/6_A*_AO_&PO=V]R:W-H965T M&UL?5/;;MLP#/T501]0Q4[69H%MH.E0;, &!!W6/BLV;0O5 MQ9/DN/O[4;+K>JO1%TFD> X/*2H;C'UV+8 G+TIJE]/6^^[ F"M;4-Q=F0XT MWM3&*N[1M USG05>19"2+-ULKIGB0M,BB[Z3+3+3>RDTG"QQO5+<_CF"-$-. M$_KJ>!!-ZX.#%5G'&_@)_E=WLFBQF:42"K031A,+=4YOD\-Q%^)CP*. P2W. M)%1R-N8Y&-^JG&Z"()!0^L# <;O '4@9B%#&[XF3SBD#<'E^9;^/M6,M9^[@ MSL@G4?DVIWM**JAY+_V#&;["5,\G2J;BO\,%)(8')9BC--+%E92]\T9-+"A% M\9=Q%SKNPWBS32;8.B"= .D,V,<\;$P4E7_AGA>9-0.Q8^\['IXX.:38FS(X M8ROB'8IWZ+T427*3L4L@FF*.8TRZC)DC&++/*=*U%,?T'3Q=AV]7%6XC?/N/ MPOTZP6Z58!<)=A^6N!;S^;\D;-%3!;:)T^1(:7H=)WGAG0?V-HUO\A8^3OL/ M;ANA'3D;CR\;^U\;XP&E;*YPA%K\8+,AH?;A>(-G.X[9:'C333^(S=^X^ M0 M2P,$% @ "F1B3;?L32&S 0 T@, !@ !X;"]W;W)KYO5%$BF>PT.*2@=CGUT#X,FKDMIEM/&^.S#FB@:4<%>F XTWE;%* M>#1MS5QG0901I"3C27+-E&@US=/H.]D\-;V7K8:3):Y72MA?1Y!FR.B&OCD> MV[KQP<'RM!,U? ?_HSM9M-C,4K8*M&N-)A:JC-YN#L==B(\!/UL8W.),0B5G M8YZ#\:7,:!($@83"!P:!VP7N0,I A#)>)DXZIPS Y?F-_3[6CK60&!Z48(["2!=74O3.&S6QH!0E7L>] MU7$?QIN;_01;!_ )P&? /N9A8Z*H_+/P(D^M&8@=>]^)\,2; \?>%,$96Q'O M4+Q#[R7?\"1EET TQ1S'&+Z,F2,8LL\I^%J*(_\'SM?AVU6%VPC?_J'P/_EW MJP2[2+#[L,2UF+]5LD5/%=@Z3I,CA>EUG.2%=Q[86Q[?Y#U\G/9OPM:M=N1L M/+YL[']EC >4DESA"#7XP69#0N7#\0;/=ARST?"FFWX0F[]Q_AM02P,$% M @ "F1B30/:H!^T 0 T@, !@ !X;"]W;W)K::*=%JFJ?1=S)YBKV3K8:3(;972IA?1Y X9'1+WQR/;=VXX&!Y MVHD:OH/[T9V,M]C,4K8*M&U1$P-51F^WAV,2XF/ SQ8&NSB34,D9\3D87\J, M;H(@D%"XP"#\=H$[D#(0>1DO$R>=4P;@\OS&?A]K][6ZK@/X\W- M?H*M _@$X#-@'_.P,5%4_EDXD:<&!V+&WG\OCF[R'C]/^39BZU9:&PO=V]R:W-H965TO&EE7$Y;[[LC8ZYL00MW@QV8<%.CU<('TS;,=19$E4!: M,;[9W#$MI*%%EGQG6V38>R4-G"UQO=;"_CR!PB&G6_KN>)%-ZZ.#%5DG&O@" M_FMWML%B,TLE-1@GT1 +=4X?ML?3/L:G@&\2!K,P.7YG?TYU1YJN0@'CZB^R\JW.;VGI():],J_ MX/ !IGIN*9F*_P174"$\*@DY2E0NK:3LG4<]L00I6KR-NS1I'\8;?IA@ZP ^ M ?@,N$]YV)@H*7\27A29Q8'8L?>=B$^\/?+0FS(Z4RO271#O@O=:;/EMQJZ1 M:(HYC3%\&3-'L, ^I^!K*4[\'SA?A^]6%>X2?/>'PKMU@OTJP3X1[/];XEK, MX:\D;-%3#;9)T^1(B;U)D[SPS@/[P-.;_ X?I_VSL(TTCES0AY=-_:\1/00I MFYLP0FWX8+.AH/;Q> AG.X[9:'CLIA_$YF]<_ )02P,$% @ "F1B3?9F MT&&U 0 T@, !D !X;"]W;W)K&UL?5-A;]P@ M#/TKB!]0^C\38U&"^=-TS#;&Q!5!&G%>)+< M,BUD1XLL^LZFR'!P2G9P-L0.6@OS>@*%8TYW],WQ*)O6!0I,0B47Q*=@?*ERF@1!H*!T@4'X M[0KWH%0@\C*>9TZZI S ]?F-_5.LW==R$1;N4?V4E6MS>J"D@EH,RCWB^!GF M>MY1,A?_%:Z@?'A0XG.4J&Q<23E8AWIF\5*T>)EVV<5]G&[2=(9M _@,X O@ M$/.P*5%4_E$X460&1V*FWO,70/1''.: M8O@Z9HE@GGU)P;=2G/@_<+X-WV\JW$?X_@^%'[8)TDV"-!*D_RUQ(V:?_)6$ MK7JJP31QFBPI<>CB)*^\R\#>\?@FO\.G:7\0II&=)1=T_F5C_VM$!UY*S M 0 T@, !D !X;"]W;W)K&UL?5-A;]P@#/TK MB!]0+LEMJTY)I%ZG:956Z=1IVV>E=2VH)US_8$Q6W6@N+W"'K2_:= H[KQI6F9[ [R.("59NMM]9(H+ M3GC@YI+XW57#&5L0[+]YZ[Z5,LB1GET TQQRGF'0= MLT0PS[ZD2+=2'-/_X.DV/-M4F$5X]I?"-PCVFP3[2+!_M\2MF.R?)&S54P6F MC=-D286#CI.\\BX#>Y/&-_D3/DW[/3>MT):&PO=V]R:W-H965T0;)JV45\ &Y_C8V/RT;H7WP$$ M\JJ5\07M0NB/C/FJ RW\C>W!X$UCG18!3=TD(:6>?*= M79G;(2AIX.R('[06[N<)E!T+NJ=OCF?9=B$Z6)GWHH4O$+[V9X<66UAJJ<%X M:0UQT!3T<7\\93$^!7R3,/K5F<1*+M:^1.-C7=!=% 0*JA 9!&Y7> *E(A'* M^#%STB5E!*[/;^SO4^U8RT5X>++JNZQ#5] '2FIHQ*#"LQT_P%S/+25S\9_@ M"@K#HQ+,45GETTJJP0>K9Q:4HL7KM$N3]G&ZN<]FV#: SP"^ !Y2'C8E2LK? MB2#*W-F1N*GWO8A/O#]R[$T5G:D5Z0[%>_1>R_TAR]DU$LTQIRF&KV.6"(;L M2PJ^E>+$_X'S;?AA4^$AP0]_*+S=)L@V";)$D/VWQ*V8N[^2L%5/-;@V39,G ME1U,FN25=QG81Y[>Y'?X-.V?A6NE\>1B [YLZG]C;0"4LKO!$>KP@RV&@B;$ MXSV>W31FDQ%L/_\@MGSC\A=02P,$% @ "F1B33>,'3*U 0 T@, !D M !X;"]W;W)K&UL?5/;;IPP$/T5RQ\0[P)MMBM MRJ:J6JF55JF:/GMA "N^4-LLZ=]W; BE#--XVQBGLT;_KB>!!MYX.#E7G/6_@._D=_MFBQA:46"K031A,+ M34'O]L=3%N)CP*. T:W.)%1R,>8I&%_J@NZ"()!0^<# <;O"/4@9B%#&KYF3 M+BD#<'U^8?\4:\=:+MS!O9$_1>V[@AXHJ:'A@_0/9OP, ME&".RD@75U(-SALULZ 4Q9^G7>BXC]--FLVP;4 R Y(%<(AYV)0H*O_(/2]S M:T9BI][W/#SQ_IA@;ZK@C*V(=RC>H?=:[M/;G%T#T1QSFF*2=/J/PL,V0;9)D$6"[,T2MV(^_)>$K7JJP+9QFARIS*#C M)*^\R\#>)?%-_H9/T_Z-VU9H1R[&X\O&_C?&>$ INQL&UL?5-A;]P@#/TKB!]0>E=2VH)US M_8$Q6W6@N+W"'K2_:= H[KQI6F9[ [R.("59FB0?F>)"TS*/OI,ICB!Q+.B.OCH>1-NYX&!EWO,6OH/[T9^,M]C"4@L%V@K4Q$!3T)O= MX9B%^!CP4\!H5V<2*CDC/@;CKBYH$@2!A,H%!NZW"]R"E('(RWB:.>F2,@#7 MYU?V+[%V7\N96[A%^4O4KBOH-24U-'R0[@''KS#7\X&2N?AO< 'IPX,2GZ-" M:>-*JL$Z5#.+EZ+X\[0+'?=QNLGV,VP;D,Z = %DZ9HE@GGU)D6ZE.*;_ MP=-M^'Y3X3["]W\I?"-_MDF018+LW1*W8OY5R58]56#:.$V65#CH.,DK[S*P M-VE\DS_AT[3?<],*;K\!UL,"8T+QT_^;*8QFPR' M_?R#V/*-R]]02P,$% @ "V1B33;2:>ZS 0 T@, !D !X;"]W;W)K M&UL?5/;CM,P$/T5RQ^P;MTLK*HDTG81 @FD:A'P M[":3Q%I?@NTTR]\S=M(0(.+%]HSGG#DS'N>C=2^^ PCD52OC"]J%T!\9\U4' M6O@[VX/!F\8Z+0*:KF6^=R#J!-**\=WN#=-"&EKFR7=V96Z'H*2!LR-^T%JX MGR=0=BSHGMXCC_GC*8GP* M^"9A]*LSB95ZH+LH"!14(3((W*[P!$I%(I3Q8^:D2\H(7)]O[.]3 M[5C+17AXLNJ[K$-7T =*:FC$H,*S'3_ 7,\])7/QG^ *"L.C$LQ16>732JK! M!ZMG%I2BQ>NT2Y/V<;KA-]@V@,\ O@ >$H!-B9+R=R*(,G=V)&[J?2_B$^^/ M''M316=J1;I#\1Z]UW*?'7)VC41SS&F*X>N8)8(A^Y*";Z4X\7_@?!M^V%1X M2/##'PJS;8)LDR!+!-E_2]R*N?\K"5OU5(-KTS1Y4MG!I$E>>9>!?>3I37Z' M3]/^6;A6&D\N-N#+IOXWU@9 *;L['*$./]AB*&A"/+[%LYO&;#*"[>&PO=V]R:W-H965T MM_ -W/?^;+S%%I9:*-!6H"8&FH+>[X^G+,3'@!\"1KLZ MDU#)!?$E&)_K@NZ"()!0N<# _7:%!Y R$'D9/V=.NJ0,P/7YC?UCK-W7;-)UAVX!D!B0+X!#SL"E15/[('2]S@R,Q4^]['IYX?TQ\;ZK@ MC*V(=UZ\]=YKN<]N>;,/3385IA*=_ M*+S;)L@V";)(D/VWQ*V8PU])V*JG"DP;I\F2"@<=)WGE70;V/HEO\AX^3?M7 M;EJA+;F@\R\;^]\@.O!2=C=^A#K_P19#0N/"\&UL?5/;;IPP$/T5RQ\0LRS;I"M RJ:J6BF15JG:/GMA "N^4-LL MR=]W; A%+>J+[1F?<^;B<3X:^^(Z $]>E=2NH)WW_9$Q5W6@N+LQ/6B\:8Q5 MW*-I6^9Z"[R.)"59FB0?F.)"TS*/OK,M<];^ ;^>W^V:+%%I18*M!-&$PM-0>]WQU,6\!'P0\#H5F<2*KD8 M\Q*,KW5!DY 02*A\4."X7>$!I Q"F,:O69,N(0-Q?7Y7_QQKQUHNW,&#D3]% M[;N"WE%20\,'Z9_-^ 7F>@Z4S,4_PA4DPD,F&*,RTL655(/S1LTJF(KBK],N M=-S'Z>:0SK1M0CH3TH5P%^.P*5#,_!/WO,RM&8F=>M_S\,2[8XJ]J8(SMB+> M8?(.O==REWW,V34(S9C3A$G7F 7!4'T)D6Z%.*7_T--M^GXSPWVD[]?1#\FV M0+8ID$6![+\E;F .?Q?)5CU58-LX38Y49M!QDE?>96#OXR.R/_!IVI^X;85V MY&(\OFSL?V.,!TPEN<$1ZO"#+8:$QH?C+9[M-&:3X4T__R"V?./R-U!+ P04 M " +9&)-X=D[]K8! #2 P &0 'AL+W=O--8IT5 T[7, M]PY$G4A:,;[;W3$MI*%EGGQG5^9V"$H:.#OB!ZV%^WT"9<>"[NF;XUFV78@. M5N:]:.$;A._]V:'%%I5::C!>6D,<- 5]W!]/6<0GP \)HU^=2:SD8NU+-#[7 M!=W%A$!!%:*"P.T*3Z!4%,(T?LV:= D9B>OSF_K'5#O6GJSZ*>O0%?2! MDAH:,:CP;,=/,-=S2\E<_!>X@D)XS 1C5%;YM))J\,'J6053T>)UVJ5)^SC= M\/N9MDW@,X$OA(<4ATV!4N8?1!!E[NQ(W-3[7L0GWA\Y]J:*SM2*=(?)>_1> MR_TMS]DU"LV8TX3A:\R"8*B^A.!;(4[\/SK?IA\V,SPD^F$=G=]M"V2; ED2 MR/XI\?"NQ"U,]BX(6_54@VO3-'E2V<&D25YYEX%]Y.E-_L*G:?\J7"N-)Q<; M\&53_QMK V JNQL&UL=5/;;MP@$/T5Q >$M=>;1"O;4C95U4JMM$K5]IFUQS8*,"[@=?KW!>PX M;NJ^ #.<<^;"D(]HGFT'X,B+DMH6M'.N/S)FJPX4MS?8@_8W#1K%G3=-RVQO M@->1I"1+=[M;IKC0M,RC[VS*' D2,A#7YU?UC[%V7\N%6WA$^5/4KBOH/24U M-'R0[@G'3S#7,C$QZA0VKB2:K .U:SB4U'\9=J%COLXW63) M3-LFI#,A70CW,0Z; L7,/W#'R]S@2,S4^YZ')TZ.J>]-%9RQ%?'.)V^]]UHF MAT/.KD%HQIPF3+K&+ CFU9<0Z5:(4_H//=VF[SOBMQ"W/W+@A;]52!:>,T65+AH.,DK[S+P#ZD\4W>X-.T?^6F%=J2"SK_ MLK'_#:(#G\KNQH]0YS_88DAH7#C>^;.9QFPR'/;S#V++-R[_ %!+ P04 M" +9&)-4]ZL1-T! !!0 &0 'AL+W=OF9$AFX1\52V 1F^<]2K'K=;#B1!5ML"I>A #].:D%I)3;4S9$#5( MH)4+XHQ$09 23KL>%YGS7621B5&SKH>+1&KDG,I?9V!BRG&([XZ7KFFU=9 B M&V@#7T%_&R[26&1EJ3H.O>I$CR34.7X*3^>CQ3O ]PXFM=DC6\E5B%=K?*IR M'-B$@$&I+0,URPV>@3%+9-+XN7#B5=(&;O=W]@^N=E/+E2IX%NQ'5^DVQX\8 M55#3D>D7,7V$I9X$HZ7XSW #9N V$Z-1"J;<%Y6CTH(O+"853M_FM>O=.BW\ M]S!_0+0$1+L ,@NYS-]338M,B@G)N?<#M;\X/$6F-Z5UNE:X,Y.\,MY;$2:/ M&;E9H@5SGC'1%K,BB&%?)2*?Q#GZ)SSRA\?>#&,7'F_5X\1/$42#T&X$_%A_M.*U"N2>@CBG8@/<_"+'+TB1P]!LA/Q8=*= M"-E<00ZR<<.G4"G&W@W^QKO.]U/DKO ?^/PX?*&RZ7J%KD*;07#7M19"@TDE M>#!=;&UL;5-M;YLP M$/XKEG] G9"TS2) :EI5F[1)4:>MGQTXP*KM8[8)W;^?;0BC*5_PW?$\S[WX MG/9HWFP#X,B[DMIFM'&NW3-FBP84MS?8@O9_*C2*.^^:FMG6 "\C24F6K%9W M3'&A:9[&V-'D*79."@U'0VRG%#=_#R"QS^B:7@(OHFY<"+ \;7D-/\']:H_& M>VQ2*84";05J8J#*Z,-Z?]@&? 3\%M#;F4U")R?$M^!\*S.Z"@6!A,(%!>Z/ M,SR"E$'(E_%GU*13RD"'BKQ.0J4-GY)T5F':E3QI2C^/IQ"Q[,?]2^T94(R$I(K AL2 MQ)GTT1@G$4\9\OWOKH.5_?W:?L'(1&S&' )'/, MA&!>?4J1+*4X))_HR3)]LUCA)M(W\^R;W;+ =E%@&P6V'UK<7;6XA/ERE83- M9JK U'&;+"FPTW&39]%I81^2>"?_X<.V_^"F%MJ2$SI_LW'^%:(#7\KJQJ]0 MXQ_8Y$BH7##OO6V&-1L&PO=V]R:W-H965TYYZ[RYWM^9FR M-WX@1'CO3=WRA7\0HIL% =\<2(/Y'>U(*]_L*&NPD%.V#WC'"-YJ4E,'41AF M08.KUE_.]=J:+>?T*.JJ)6OF\6/38/;GGM3TO/"1_['P7.T/0BT$RWF']^2% MB!_=FLE9T%O95@UI>45;CY'=PO^$9D^H4 2-^%F1,[\8>RJ45TK?U.3K=N&' MRB-2DXU0)K!\G,B*U+6R)/WX;8WZO:8B7HX_K#_JX&4PKYB3%:U_55MQ6/B% M[VW)#A]K\4S/7X@-*/4]&_TWYLC%[2Q5J0K#7XWSZK5 MS[-YDY>6!A,B2XAZ DHF";$EQ/\(V20AL83D5H74$M);"9DE9+<2#EG].PQ4W$=5H6-9KDLB(U:U-]?OY-?C,O5TQ+EX3PX*4,68UF#B4/]@I0142@"EPE$RF.)"*;L;"2<%15) I'1$ M $PQ$DD&BF2 ;<2#2:]B"2=R%@.ZN2 CE.)J_SVC!6@2 &(.*6\@C CI5R" M(B5@P"GE53FHLCAQR\QT\! 9I>.Y12&\Y82 3R.90R.[%@),Y.YF@@;>)E/- M@^#- &=7A0C)N!61T"O#]T=-GLVZ2[<[ CH]J(<,0&W,@+ZM!P<"NDPN]&4 MNW!'(Z"E2^1J94"%3FG!78V MBZC$1-PSR*H(5/WC"J&V[9)S<#AX.*<5I>_ M[YCMJY9[KU3((U\?S#M*!9%FPSN9\8.\;_:3FNR$&N9RS,RERTP$[>R%,NAO MM&PO=V]R:W-H965T MV$Z=_7VS"$T+0OV+X^Y]R%ZYOVC+^(&D!ZKY2T(O-K*;LU0J*H@6+QP#IH MU4W).,52'7F%1,FZJ6VH#RM,,5? /YO3MP=4*#RJFAT(J&M1Z',O.?PO4^T7@#^-% M+T9[3V=R9.Q%'SZ?,C_0 0&!0FH%K)8+;($0+:3"^.4T_<&E)H[W;^H?3>XJ MER,6L&7D9W.2=>8_^MX)2GPF\IGUG\#EL_ ]E_P7N !1LG##W&*+EK(8386 M$XTPR]4U9'<+"0<$4@$,441S46RB&WIT[6![BU@^3F+XI\C^KLA5F/%LL6+# MC\=9AG\12&8%$B.07%4[F53;8E8&TUI,' 23K5D3((*/GA0W5^K^3@<")12;U=JS^V4L ?).C< T3"%\S]0 M2P,$% @ "V1B30OJT9 3 @ !P8 !D !X;"]W;W)K&ULC53;CILP$/T5Q >LN2201("T2;5JI5:*MFK[[)!)0&MCUC9A M^_<=&\+FXJZ6!VP/9\Z98^S)>B%?5 6@O3?.&I7[E=;MBA!55L"I>A M-/CE M("2G&I?R2%0K@>YM$F@TJQO82D]UG%/Y=PU,]+D? M^N? #&+;_O<#TQ%P*#4AH+B<((-,&:8L([7D=2?-$WBY?S,_F3-HYD= M5; 1[$^]UU7N+WQO#P?:,?TL^J\P&IK[WNC^.YR (=Q4@AJE8,J^O;)36O"1 M!4OA]&T8Z\:._1]"EV21UN247UXJ#/-H.I+Q2=(UM?Q?1JP4/0FC >H('/"(5=N5IP>"@S33%N1Q:T[#0HAW;+IEZ?_$/ M4$L#!!0 ( MD8DW#(''5B0, &\0 9 >&PO=V]R:W-H965T[7]/.[&RG[6]6HS(+Q )J M^_9-(+J2W*C[8R%X[CGWAIMCXO@@ZH]FPWGK_2V+JIGXF[;=W@5!L]CP,FM& M8LLK^ M?S2I?])4@>?W1_:'KGA9S'O6\)DH?N?+=C/Q$]];\E6V*]HW<7CBNJ#8]W3U MW_B>%Q*N,I$:"U$TW7]OL6M:46H6F4J9_>VO>=5=#YK_& 8'8!V 3P%2^U( MT0'D,R"Z&!#I@.C6E&(=$-^J0'4 O36 Z0!V:T"B Y); U(=D-X:@,+CFPN- MD*!_Y5T/S;,VFXYK;I*\GR=Y,6&(/9)$\B9 M/TT_AJ(WOIFZM)?QE>!PZS.^BE:>=[D"R$J+EDC &PO=V]R:W-H965TL*]][N%W^.-\X.)5U@#*>VM9)PN_ M5JK?(R3/-;14/O >.KU3<=%2I4MQ1;(70"^VJ64H#(($M;3I_#*W:T=1YORF M6-/!47CRUK94_'T"QH?"Q_[[PDMSK9590&7>TRO\ /6S/PI=H=GETK30R89W MGH"J\!_Q_I 8O17\:F"0B[EGDIPX?S7%UTOA!P8(&)R5<:!ZN,,!&#-&&N// MY.G/MS2-R_F[^V>;76U/X;W ' MIN6&1-_CS)FT5^]\DXJWDXM&:>G;.#:='8=QA\13F[LAG!K"N0'_OR&:&J)5 M QK);-1GJFB9"SYX8GQ9/37?!-Y'^F&>S:)]=G9/IY5Z]5Z&$AFB9TLL8,E7;%L-1N644(6+#A-<4@"-PMQLA 'RV[%LM5L6,B& MY1/&)-WAU V3.&$2!TRV@MEJ-C#)YB7A@&19FI$5#%K\!.90^D[%M>FD=^)* M_T_VJZ\X5Z!-@P<=KM;GX%PPJ)29IGHNQM-@+!3OIX,.S:=M^0]02P,$% M @ "V1B3;ZT)@T* @ G 4 !D !X;"]W;W)K&ULC539;MLP$/P501\0ZK130Q80'T$+M("1(NTS+:\.A!05DK;2OR^O*+(M M./YG9F=7U&8]XR^B!I#>&R6M6/JUE-T"(5'40+&X8QVTZJ1DG&*IMKQ" MHN. #X9$"8J"8(8H;EH_STQLQ_.,'25I6MAQ3QPIQ?S?"@CKEW[HOP>>FJJ6 M.H#RK,,5_ ;YW.VXVJ%!Y=!0:$7#6H]#N?0?PL4VT7@#^-- +T9K3U>R9^Q% M;WX'6:_I!2$\?K=_5'4[NJ98\%K!GYVQQD MO?3O?>\ )3X2^<3Z[^#J27W/%?\33D 47#M1.0I&A/GWBJ.0C#H5987B-_ML M6O/L[(/PC)34+B",E7,Z2.D%YD0+9VT\P-ECC/ M..L];J]#A_6M"Q>I>EV%#IJW8\Y4/X6*GO(H"3)TTD(.L[*8:(29S<\AFVM( M.""0,C"XB*9G2>8'V-F-U?>/A49'M3Y,QF/-FLV/#C<971MVF!9%(@ M,0+)6;?#BVY;3&HPK<'$::!_%QVYQLVF<)LOZFT_U[,%HM'5HL K\YT+KV#' M5NKFC*+#*'F(]-6\B*_"Q3JSJU?F%=-*[P]D^J#,->V9$R" MLA_<*>>U&I7#AD I]7*NUMP.#+N1K'.S$ T#.?\/4$L#!!0 ( MD8DT: MR*T_&P( %\& 9 >&PO=V]R:W-H965T M!QX0S%HA7U4!H(.WBM=J&19:-PN$U*Z BJE'T4!M>@Y"5DR;JCPBU4A@>R>J M.,)1E*"*E7689ZYM*_-,G#0O:]C*0)VJBLE_3\!%NPQGX:7AN3P6VC:@/&O8 M$7Z"_M5LI:FAWF5?5E"K4M2!A,,R_#Q;;*CE'?"[A%9=E0.;Y$6(5UOYME^& MD9T0<-AIZ\#,XPPKX-P:F6G\]9YA/Z057I1P'N!3/RKB#V@OA> ?$"@&]5Y!X03(0H&ZQW.JOF69Y)D4; MR.[]:9A]36>+Q.SOSC:Z[71]9@.4:3WGF. ,G:V19YXZ!M\P\2VSFF!NB?68 M2-);Y,N')IMW39!)VL?%DW&QTY,K?1H-DHR1X8*L.V3ND-HA\3R)4TH'><8< MQ?,(#[#-&'N@B$P.1"8&HM,& M=-* ?KP'=+0B V(])N(TLK_!%HPY.H%MQMA#A MS1%U!^D@A ;C&3T:T\+<]GV%PT';XMR497?G=14M&G^=H_Z;DO\'4$L#!!0 M ( MD8DV./J.W7P( !,) 9 >&PO=V]R:W-H965T39$60FDO52JT4;;7MLY,X :W!U';"]N]K&X<- M<++B);XP,V>.?6([;1A_$SDATGDO:266;BYE_>QYXI"3$HLG5I-*?3DQ7F*I MAOSLB9H3?#2DDGJA[R=>B8O*S5(SM^-9RBZ2%A79<4=GLF?L30^^'Y>NKQT12@Y22V#57,F:4*J5E(^_5M3M8FKB??^F_M4DKY+9 M8T'6C/XICC)?NG/7.9(3OE#YPIIOQ":$7,=F_X-<"55P[43%.# JS*]SN C) M2JNBK)3XO6V+RK2-U;_18$)H"6%'".)/"9$E1%,)L27$4PG($M '86:6M\W= M+.8&2YREG#4.;^NAQKKL@F>DMNN@)\WNF&]J/86:O69AG*3>50M9S*K%A#U, MU,>L 4P?L1DCDGD?L@5$/B">RJ-+)@23"0T_[AF=#8Q"F(&/#819P$8BT$@T M%D#^P B$"09&/L?TC,2@D1@0&&S,&L)$'8C"AH@'0:%T@H>31 MPL!G6@ <1L.B7@.@L9=P8N5[=W>'?B[\Q/Q<5,+9,ZFN(7-9G!B31(GZ3THN M5R^4;D#)2>KN3/5Y>TVW \EJ^P3QNG=0]A]02P,$% @ "V1B3=^"YD,8 M! F1, !D !X;"]W;W)K&ULC5C;CNHV%/V5 M*!] 8N=B!P'2 -4:J71J=H^9\!<=)*8)IGA].^;BX?!]@HP#Y/$K'U9V=O+ MCB<76?ZLCD+4SJ\\*ZJI>ZSK\]CSJNU1Y&DUDF=1-+_L99FG=?-8'KSJ7(IT MUQGEF4=]/_;R]%2XLTDW]E;.)O*CSDZ%>"N=ZB//T_*_NH2]VO@Q^EP MK-L!;S8YIP?QIZC_.K^5S9-W];([Y:*H3K)P2K&?NB]DO G\UJ!#_'T2E^KF MWFFIO$OYLWWX;3=U_38CD8EMW;I(F\NG6(@L:STU>?RKG+K7F*WA[?V7]U5' MOB'SGE9B(;-_3KOZ.'6YZ^S$/OW(ZA_RLA&*4.0ZBOWOXE-D#;S-I(FQE5G5 M_7>V'U4M<^6E225/?_774]%=+\K_EQDVH,J 7@V:V/<, F40?!N$=PU"91 ^ M&R%2!M&S$6)E$'\;L+L&3!FP9R-P9<"_#>*NXGTYNOHNTSJ=34IY<)"$@]% ME;=WLA&U^6=4U5&.(Z3J,J+.IQ/.]NCFD_E09=%+1Y5 MT!ZJ*E?_%J*4IUF(PE?#CV*WU]80S:=-OA,_A?[5/"JSBT:635&)NBUD'2BQ MG87W:+)"U#ITB-^%.+5GZ\!*>9+RV6Z^;F9A;#,2I5AK2Y&;QU$L15E:)I/' MWX$T'&-:Q_/U*_OG3KP1\Y2W8BG+/\5&[V V$Q-C+X_4\_66(]SG,73Z&B)!LRBQ^ S3))>0AY\"!H1D4E@S )#62RPYXXO RQ] M1,*='#XD6;U+Q.,7HREN1@=HR0!N#"5 ,=['XAO( (.JVF0%S<=@HB6.W MW7U,M?J0ZE+8E?:, &%77DH$]M9[A&^I#?;O#B5)ZEX> $?3C!"O0#XNS3). MO"+Y.$0HY^C:^<.-&4&=.;U" ;=F=$MO1D"?!+H/ ".8>>T'@$']!X!E*??Z M3W3VR:^$VG7S5QNLY:'6]H-V9AUGO'ML1P;'OD"3)0+L#W8F[$:,-_I^H/R> MJUU1M\&3U&90Z<:)K91:F.SC.W.V>S/#CIM2;+5=IF:M^D&NWVC9#$-J-$[* M\_]02P,$% @ "V1B3:4=,^HL @ Z 8 !D !X;"]W;W)K&ULC57M;ILP%'T5Q /4?"8A(D@-U;1)FQ1U6O?;(3D9'E4-70R(HWCH#CQKWWU[GOF02+ M>*J@DY.Y8ZSL.7\VBV^'C>L91<"@4(:"ZN$".3!FF+2./P.I.]8TB=/YE?V+ M-:_-[*F$G+/?U4&5&W?E.@:G\->AWLS"!.W>V7?:K=312Q8DJY1<#-& V?:88(+Q1P31[&.) M "NQ#6[2@[<%\EO$8H57"%$3H+,B&,:?N?T8\T;($A6RO"$( M/0\G6*$$J_]O5XY@WMNN!"V2("K?L:D;(WI8O4_HQ$#+^7$BD_Y0@SC95BJ= M@I\;94[B)#JVZ_O ])=9?&O:N.T[KS3]'?"#BE/52&?/E>Y>ML<<.5>@-7IW M^M\K];4S+A@BMK M"C0# Q#0 &0 'AL+W=O^WVV/K"XZCY]8(W_9\[8NA'QL#WYW:EFQ MZYWJRL<@2/RZ*!MWM>C''MK5@I]%53;LH76Z6OGD3U%V9[=U0J MSYR_J(=ONZ4;J!FQBFV%"E'(RX5M6%6I2'(>?\:@[L14CO/[M^A?^N1E,L]% MQS:\^EWNQ''I9JZS8_OB7(E'?OW*QH1BUQFS_\XNK)+F:B:2L>55U_]WMN=. M\'J,(J=2%Z_#M6SZZW6,_^9&.^#H@).#9'_D$(X.X;M#U"<_S*Q/]7,ABM6B MY5>G'=[6J5!% 7>A7,RM&NS7KO]-9MO)TYMFF$66Q#$@#8I(4$2 (@T4 M&2!(DI2FQ"0E)BBQ1HD-RB<(8["M6T*"$@*4:*#$7+@4G*OT "9?0<)%#HH2TKNC& MV1DPC2TA:,D#I7G]78]&F>U=#VV.L J]/+%,A^X-0#0'""TA:-4#)7N]70*A M^RA'2&T%3 L?*.7K'1-,Z=M;)M#"!TKY>M,AF <,X M2U(+"^D.@$0',%KG:'2S@'F0Q*GM.TWW *1Z@*7](JUM)+1MU-9H-)]NF(;R MSX*BM8W45U\O+<+(UAB1UC]2^M<+BS"R8FA=(_71UVL*S:_^APM'ZQ\I_1LE M9>J?1/FSC6;-VD._)^^<+3\W0FWI9J/3OO\>U495&U_+\\"P>W\/,QPF?A3M MH6PZYYD+N0WN-ZM[S@63TPP\.<&C/+],#Q7;"W6;ROMVV,0/#X*?Q@.*/YV2 M5O\ 4$L#!!0 ( MD8DT8?RXJ]0, -$3 9 >&PO=V]R:W-H965T M^(MWO+KJ]EMW5*KW?M15TZW]8]^?G\*P MVQY577:!/JMF^&:OV[KLA\?V$';G5I6[J5-=A3**TK N3XV_64UMK^UFI2]] M=6K4:^MUE[HNVY\OJM+7M2_\WPV?3X=C/S:$F]6Y/*C_5/__^;4=GL);E-VI M5DUWTHW7JOW:?Q9/+W$\=I@47T[JVBWNO7$J;UI_&Q_^WJW]:!R1JM2V'T.4 MP^5=?5!5-48:QO'=!/5OGF/'Y?WOZ)^FR0^3>2L[]4%77T^[_KCV<]_;J7UY MJ?K/^OJ7,A-*?,_,_A_UKJI!/HYD\-CJJIL^O>VEZW5MH@Q#J.R?_7([O6#S)(3?;L7%*Q?3= M,/AN:'W?D$A6X?L8R&A>9HU<:,1-$0[1;Q826;Q(ISN)% <@.$:: L1W 3)K MC+,FF33-I)$9R4@P(XVA40R,XF30:<30%M"F##)$-$ MF*<(A'" FD7CY<]8@RQAG!AR!7!*;:=9E"V,.!<([[.0#\!G1,E=ZC.11PP8 M G,N$.CV4D(BR9 A,.8",.P@:$3+Y20#P2T&C+I K-L0&M$R>7E9M&(EBQRVY/$R$N O .C$=W!F.5$#/<2 >S=Y0,0F#T,O$<\VC$;T:/(P]A)@3]SB MQ4!+!+1-HQ'=[XR"QQ&#+Q'X#HZ%BR/SF@E33X!ZMS"-G!65I:DLF+J$,/F$ MR+=7%!(1YX.Q)T"T@Z,1W:TH"@KF'1%3U"/P;1S)+>LS2C/V/6'RZ9&Z'HF( M&!^,/:'MWL:10&U/0<[@2!A\ N 34YL0)IK01F[C:$3W./*[(V'R"9%OXTAN M^5[D 5>=$ :? /@ND86SJ!*1)%SY'6/X8P2_\V<1B+B]),;DQZC,MXDTHKN" M*PV8W,48_1BA;P,9NY7^D#N1<%:8_?B10A^)V-PQ_^?1EF\#&8-"?\B=O<3# MQ8E*K=K#=);4>5M]:::#K$7K[;SJ64XG,G_D\V'7OV5[.#6=]Z;[7M?3Z MZUX-HXF"(;5'5>YN#Y7:]^-M-MRW\R'3_-#KLSE "V^G>)M?4$L#!!0 ( M MD8DV$5&PO=V]R:W-H965T)%E@#*>V6TEDN_5*I9("2+$AB1#[R!6I\\;.B50T[X 8[D3-43;S]#5T_B>UWQ7^$"5,--)CI&P:FT7Z\X2\59IZ)38>35K55M MU]:=)'%'NTW '0'W!!W['B'J"-$[X7Z$N"/$_QLAZ0C)* )RM=MF;H@B>29X MZPEW'1IB;EVX2/3O*HS3_AU[IOLIM?>21]$L0QP<^U,FT9>/LA\HC-I1SY5^%B'=[P;_30<3/B7=Y-K&]$G*I:>GNN M]%.P%_;(N0*=?O"@GT"IAV1O4#@JLTWU7KA1X0S%FVX*HGX4YW\ 4$L#!!0 M ( MD8DTM;DQQ+ ( (L' 9 >&PO=V]R:W-H965T9!+0&4]L)V[^O;0@E M89+-"[YPYLR9 QZGC9"O*@?0WEO)*[7T#*/;WM46E1=BQ& M2LG>VK&HW-AT_.
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end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 112 179 1 false 44 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cytrx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://cytrx.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://cytrx.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://cytrx.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://cytrx.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Description of Company and Basis of Presentation Sheet http://cytrx.com/role/DescriptionOfCompanyAndBasisOfPresentation Description of Company and Basis of Presentation Notes 6 false false R7.htm 00000007 - Disclosure - Foreign Currency Remeasurement Sheet http://cytrx.com/role/ForeignCurrencyRemeasurement Foreign Currency Remeasurement Notes 7 false false R8.htm 00000008 - Disclosure - Recently Adopted Accounting Pronouncement Sheet http://cytrx.com/role/RecentlyAdoptedAccountingPronouncement Recently Adopted Accounting Pronouncement Notes 8 false false R9.htm 00000009 - Disclosure - Recent Accounting Pronouncements Sheet http://cytrx.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 9 false false R10.htm 00000010 - Disclosure - Term Loan Sheet http://cytrx.com/role/TermLoan Term Loan Notes 10 false false R11.htm 00000011 - Disclosure - Basic and Diluted Net Loss Per Common Share Sheet http://cytrx.com/role/BasicAndDilutedNetLossPerCommonShare Basic and Diluted Net Loss Per Common Share Notes 11 false false R12.htm 00000012 - Disclosure - Warrant Liabilities Sheet http://cytrx.com/role/WarrantLiabilities Warrant Liabilities Notes 12 false false R13.htm 00000013 - Disclosure - Stock Based Compensation Sheet http://cytrx.com/role/StockBasedCompensation Stock Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Fair Value Measurements Sheet http://cytrx.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 00000015 - Disclosure - Liquidity and Capital Resources Sheet http://cytrx.com/role/LiquidityAndCapitalResources Liquidity and Capital Resources Notes 15 false false R16.htm 00000016 - Disclosure - Equity Transactions Sheet http://cytrx.com/role/EquityTransactions Equity Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Income Taxes Sheet http://cytrx.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 00000018 - Disclosure - Commitments and Contingencies Sheet http://cytrx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 00000019 - Disclosure - Term Loan (Tables) Sheet http://cytrx.com/role/TermLoanTables Term Loan (Tables) Tables http://cytrx.com/role/TermLoan 19 false false R20.htm 00000020 - Disclosure - Warrant Liabilities (Tables) Sheet http://cytrx.com/role/WarrantLiabilitiesTables Warrant Liabilities (Tables) Tables http://cytrx.com/role/WarrantLiabilities 20 false false R21.htm 00000021 - Disclosure - Stock Based Compensation (Tables) Sheet http://cytrx.com/role/StockBasedCompensationTables Stock Based Compensation (Tables) Tables http://cytrx.com/role/StockBasedCompensation 21 false false R22.htm 00000022 - Disclosure - Fair Value Measurements (Tables) Sheet http://cytrx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://cytrx.com/role/FairValueMeasurements 22 false false R23.htm 00000023 - Disclosure - Description of Company and Basis of Presentation (Details Narrative) Sheet http://cytrx.com/role/DescriptionOfCompanyAndBasisOfPresentationDetailsNarrative Description of Company and Basis of Presentation (Details Narrative) Details http://cytrx.com/role/DescriptionOfCompanyAndBasisOfPresentation 23 false false R24.htm 00000024 - Disclosure - Foreign Currency Remeasurement (Details Narrative) Sheet http://cytrx.com/role/ForeignCurrencyRemeasurementDetailsNarrative Foreign Currency Remeasurement (Details Narrative) Details http://cytrx.com/role/ForeignCurrencyRemeasurement 24 false false R25.htm 00000025 - Disclosure - Recently Adopted Accounting Pronouncement (Details Narrative) Sheet http://cytrx.com/role/RecentlyAdoptedAccountingPronouncementDetailsNarrative Recently Adopted Accounting Pronouncement (Details Narrative) Details 25 false false R26.htm 00000026 - Disclosure - Term Loan (Details Narrative) Sheet http://cytrx.com/role/TermLoanDetailsNarrative Term Loan (Details Narrative) Details http://cytrx.com/role/TermLoanTables 26 false false R27.htm 00000027 - Disclosure - Term Loan - Schedule of Term Loan (Details) Sheet http://cytrx.com/role/TermLoan-ScheduleOfTermLoanDetails Term Loan - Schedule of Term Loan (Details) Details 27 false false R28.htm 00000028 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details Narrative) Sheet http://cytrx.com/role/BasicAndDilutedNetLossPerCommonShareDetailsNarrative Basic and Diluted Net Loss Per Common Share (Details Narrative) Details http://cytrx.com/role/BasicAndDilutedNetLossPerCommonShare 28 false false R29.htm 00000029 - Disclosure - Warrant Liabilities (Details Narrative) Sheet http://cytrx.com/role/WarrantLiabilitiesDetailsNarrative Warrant Liabilities (Details Narrative) Details http://cytrx.com/role/WarrantLiabilitiesTables 29 false false R30.htm 00000030 - Disclosure - Warrant Liabilities - Schedule of Weighted-average Assumptions (Details) Sheet http://cytrx.com/role/WarrantLiabilities-ScheduleOfWeighted-averageAssumptionsDetails Warrant Liabilities - Schedule of Weighted-average Assumptions (Details) Details 30 false false R31.htm 00000031 - Disclosure - Stock Based Compensation (Details Narrative) Sheet http://cytrx.com/role/StockBasedCompensationDetailsNarrative Stock Based Compensation (Details Narrative) Details http://cytrx.com/role/StockBasedCompensationTables 31 false false R32.htm 00000032 - Disclosure - Stock Based Compensation - Schedule of Total Stock-based Compensation Expense from Stock Options and Warrants (Details) Sheet http://cytrx.com/role/StockBasedCompensation-ScheduleOfTotalStock-basedCompensationExpenseFromStockOptionsAndWarrantsDetails Stock Based Compensation - Schedule of Total Stock-based Compensation Expense from Stock Options and Warrants (Details) Details 32 false false R33.htm 00000033 - Disclosure - Stock Based Compensation - Schedule of Share-based Payment Award, Fair Value of the Stock Options Granted, Assumptions (Details) Sheet http://cytrx.com/role/StockBasedCompensation-ScheduleOfShare-basedPaymentAwardFairValueOfStockOptionsGrantedAssumptionsDetails Stock Based Compensation - Schedule of Share-based Payment Award, Fair Value of the Stock Options Granted, Assumptions (Details) Details 33 false false R34.htm 00000034 - Disclosure - Stock Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) Sheet http://cytrx.com/role/StockBasedCompensation-ScheduleOfShare-basedCompensationStockOptionsActivityDetails Stock Based Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Details) Details 34 false false R35.htm 00000035 - Disclosure - Stock Based Compensation - Schedule of Outstanding Stock Options (Details) Sheet http://cytrx.com/role/StockBasedCompensation-ScheduleOfOutstandingStockOptionsDetails Stock Based Compensation - Schedule of Outstanding Stock Options (Details) Details 35 false false R36.htm 00000036 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://cytrx.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://cytrx.com/role/FairValueMeasurementsTables 36 false false R37.htm 00000037 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurements by Level for Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Sheet http://cytrx.com/role/FairValueMeasurements-ScheduleOfFairValueMeasurementsByLevelForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Schedule of Fair Value Measurements by Level for Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) Details 37 false false R38.htm 00000038 - Disclosure - Liquidity and Capital Resources (Details Narrative) Sheet http://cytrx.com/role/LiquidityAndCapitalResourcesDetailsNarrative Liquidity and Capital Resources (Details Narrative) Details http://cytrx.com/role/LiquidityAndCapitalResources 38 false false R39.htm 00000039 - Disclosure - Equity Transactions (Details Narrative) Sheet http://cytrx.com/role/EquityTransactionsDetailsNarrative Equity Transactions (Details Narrative) Details http://cytrx.com/role/EquityTransactions 39 false false R40.htm 00000040 - Disclosure - Income Taxes (Details Narrative) Sheet http://cytrx.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://cytrx.com/role/IncomeTaxes 40 false false R41.htm 00000041 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://cytrx.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://cytrx.com/role/CommitmentsAndContingencies 41 false false All Reports Book All Reports cytr-20180930.xml cytr-20180930.xsd cytr-20180930_cal.xml cytr-20180930_def.xml cytr-20180930_lab.xml cytr-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 59 0001493152-18-015120-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-015120-xbrl.zip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